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Introduction 
 
The aim of this work is mainly to show the viable applications of the Radio Frequency 
Identification technology (RFID) inside the Pharmaceutical Supply Chain, by trying to 
understand the real scope of this technology in a complex and regulated industry as the 
pharmaceutical one. 
 
This purpose will be addressed, by organising the thesis as follow. 
In the first chapter it is explained the basics of RFID technology and discuss the current 
state of art in the standardisation of frequencies and hardware used. Then this section 
shows the main applications both in consumer and business-to-business context and in 
the end the main problems faced by a company in approaching this technology. 
The second chapter describes the critical parties involved in the pharmaceutical industry 
from the manufacturer to the end-consumer, then examines the essential features of the 
pharmaceutical supply chain and the key concerns that this industry has to face to be 
really efficient and to deliver drugs in a safe, integrated and consistent manner. 
In the last section, finally, the two predominant topics of the work are blended together, 
by examining how the RFID technology can be used inside the Pharmaceutical Supply 
Chain and the principal fields of application in the light of the main problems faced by 
this industry and described in the previous section. 
 
The work does not want to look at the RFID technology as the panacea of all the issues 
inside this industry, but it want to try simply to fill a gap in the literature about the all 
possible uses of this technology inside the above mentioned industry. 
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1.  PRELIMINARY KNOWLEDGE ABOUT RADIO-
FREQUENCY IDENTIFICATION 
 
Radio-Frequency Identification (RFID) technology is classified as a wireless automatic 
identification and data capture (AIDC) technology. AIDC technologies include 
barcoding, optical recognition, biometrics, card technology, touch or contact memory 
technology, and RFID technology. Some auto-ID technologies, such as barcode 
systems, often require a person to manually scan a label or tag to capture the data; RFID 
is designed to enable readers to capture data on tags and transmit it to a computer 
system—without needing a person to be involved. 
Wireless technologies represent an emerging area of growth and are important even in 
mobile commerce (m-commerce) applications. Even though the terms ‘‘mobile’’ and 
‘‘wireless’’ are used interchangeably, they actually have different meanings. Mobile 
means positioning a mobile device as any terminal that can be used on the move, while 
wireless refers to the transmission of data over radio waves, meaning that a wireless 
device is any terminal that uses a wireless network to either send or receive data.  
 
Wireless networks can be divided into four main categories:  
− Wireless Personal Area Network (WPAN), which can be used to allow PCs, PDAs, 
mobile phones to detect each other and interact; 
− Wireless Local Area Network (WLAN), which provides simple Internet or intranet 
access to PCs, PDAs, and laptops equipped with a wireless network card; 
− Wireless Metropolitan Area Network (WMAN); and 
− Wireless Wide Area Network (WWAN), which is a location technology based on a 
system of satellites orbiting the earth (S. F. Wamba, 2008). 
 
Radio-frequency identification (RFID) is a generic term that is used to describe a 
system that transmits the identity (in the form of a unique serial number) of an object or 
person wirelessly, using radio waves [3]. This information is transferred data from an 
electronic tag, called RFID tag, attached to an object, through a reader for the purpose 
of identifying and tracking the object. The tag's information is stored electronically. 
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RFID is a semiconductor-based technology that can be used to identify objects. In its 
most basic design, an RFID tag can be thought of as a wireless barcode [9]. 
The basic premise behind RFID systems is that you mark items with tags. These tags 
contain transponders that emit messages readable by specialised RFID readers. A reader 
retrieves information about the ID number from a database, and acts upon it 
accordingly. RFID tags can also contain writable memory, which can store information 
for transfer to various RFID readers in different locations (Weinstein R., 2005).  
The RFID tag includes a small RF transmitter and receiver. An RFID reader transmits 
an encoded radio signal to interrogate the tag. The tag receives the message and 
responds with its identification information.  
RFID is a superior and more efficient way of identifying objects than manual system or 
use of barcode systems that have been in use since the 1970s. It is not necessary to 
"show" the tag to the reader device, as with a bar code. In other words it does not 
require line of sight to "see" an RFID tag, the tag can be read inside a case, carton, box 
or other container, and unlike barcodes RFID tags can be read hundreds at a time. Bar 
codes can only be read one at a time [9]. 
 
RFID systems have three fundamental capabilities.  
First, RFID is a means to wirelessly identify people and objects; his ability to identify 
things without human manipulation is an important service delivery advantage. 
Consider, for example, a hospital patient. Nurses need to be able to verify the delivery 
of medicine to the patient, and it is an important advantage of RFID that this can be 
done 24/7 without disturbing the individual, who might be unable to communicate or 
simply resting. RFID can help nurses serve patients better by obviating the need to 
disturb the patient to access a barcoded label; instead RFID can be read wirelessly 
through materials. 
The second fundamental capability of some RFID systems is to automatically generate 
data that can be used to track and locate tagged items; fundamentally most RFID 
systems generate information based on wireless communications between tags and 
readers that can be used to locate the tag either directly or indirectly. 
A third fundamental capability that some RFID systems have is to sense the 
surroundings; some types of tags include a variety of environmental monitoring 
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capabilities, such as the ability to track the ambient temperature, which enables the tag 
to act as a mobile sensor to wirelessly collect information about its immediate 
environmental conditions (Geraldo Ferrer, 2010). 
This technology enables organisations to deliver value-added applications related to the 
tracking and intelligent management of any entity tagged with an RFID chip.  
The technology has been around for more than 50 years; however, it has not been 
widely used. Since 2003, when Wal-Mart announced its intention to introduce an RFID 
application, it has brought new business opportunities to many information companies. 
With both identification and tracking characteristics, RFID may dramatically change the 
organisation’s capability to obtain real-time information about the location and 
properties of tagged objects, such as people or products (Shiou-Fen Tzeng, 2008).  
Current research and development on RFID focus on the manufacturing and retail 
sectors to improve supply-chain efficiency and to learn more about consumer 
behaviour. Healthcare is believed to be its next home (Gunasekaran, 2005). 
 
1.1 The hardware for RFID 
Tags and readers are the main components of an RFID system. An RFID tag is often 
confused with an RFID label. A tag is a transponder mounted on a substrate. It can be 
embedded in packaging or stuck on with adhesive. An RFID label is a transponder 
sandwiched between a layer with adhesive and paper that can be printed on [1].  
Basically, an RFID system is composed of three layers:  
− a tag containing a chip, which is attached to or embedded in a physical object to be 
identified;  
− a reader and its antennas that allow tags to be interrogated and to respond without 
making contact; and 
− a computer equipped with a middleware application that manages the RFID 
equipment, filters data, and interacts with enterprise applications (Samuel Fosso 
Wamba, 2008). 
 
An RFID reader typically has an RF front end that serves one or more antennas, an RF 
signal processor, an air-protocol processing engine that implements the air-protocol 
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message decoder/encoder and state machine and algorithms, and the network interface 
processor to communicate with the upstream network elements.  
There are different types of reader designs based on different factors:  
− Number of antennas: multiple (typically 4 to 8) antennas or a single integrated 
antenna (readers can have internal or external antennas); 
− Processing complexity: data processing includes business intelligence (sometimes 
referred to as “smart” readers), or just RF intelligence (sometimes referred to as 
“thin” readers); 
− Tag access functions: some perform all air-protocol operations (read, write, lock and 
kill tags), others just inventory the tags; 
− Connectivity: Ethernet, serial, or wireless (Readers can also have input/output ports 
for connecting to external devices. An output port might connect to a program logic 
controller, conveyor sorter or other device controlled by the reader. Readers also 
have ports for connecting to a computer or network.) 
− Number of digital I/O ports: none or multiple (typically 1-4). 
In its simplest classification, radio-frequency identification (RFID) tags can be 
separated in two types: active (where the tag has a battery) or passive (where the tags do 
not have its own source of energy) (P. Krishna, 2007). 
 
1.1.1 Active RFID Systems 
Active tags are used on large assets, such as cargo containers, rail cars and large 
reusable containers, which need to be tracked over long distances (in a distribution yard, 
for example). They usually operate at 455 MHz, 2.45 GHz, or 5.8 Ghz, and they 
typically have a read range of 20 meters to 100 meters. 
Generally, there are two types of active tags: transponders and beacons.  
− Active transponders are woken up when they receive a signal from a reader. These 
are used in toll payment collection, checkpoint control and other systems. When a 
car with an active transponder approaches a tollbooth, a reader at the booth sends 
out a signal that wakes up the transponder on the car windshield. The transponder 
then broadcasts its unique ID to the reader. Transponders conserve battery life by 
having the tag broadcast its signal only when it is within range of a reader.  
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− Beacons are used in most real-time locating systems (RTLS), where the precise 
location of an asset needs to be tracked. In an RTLS, a beacon emits a signal with its 
unique identifier at pre-set intervals (it could be every three seconds or once a day, 
depending on how important it is to know the location of an asset at a particular 
moment in time). The beacon's signal is picked up by at least three reader antennas 
positioned around the perimeter of the area where assets are being tracked. It has 
been used in a variety of contexts to locate individuals, such as in amusement parks 
and in prisons. RTLS has been used in ports to facilitate the location of a specific 
container among thousands, and at automobile distribution centers to help finding a 
specific vehicle in the lot. Its use in manufacturing sites has helped locating 
individually tagged items that may be lost in a large job shop. 
 
Active tags have a read range of up to 100 meters and can be read reliably because they 
broadcast a signal to the reader (some systems can be affected by rain). They generally 
cost from $10 to $50, depending on the amount of memory, the battery life required, 
whether the tag includes an on-board temperature sensor or other sensors, and the 
ruggedness required. A thicker, more durable plastic housing will increase the cost. 
Active tags are not mass-produced in high volume and don't have problems with 
antennas detaching from the microchip because they are usually housed in protective 
plastic [2]. 
 
1.1.2 Passive RFID Systems 
Passive RFID tags have no power source and no transmitter. They are cheaper than 
active tags and require no maintenance, which is why retailers and manufacturers are 
looking to use passive tags in their supply chains. They have a much shorter read range 
than active tags (a few centimetres to 10 metres). A passive RFID transponder consists 
of a microchip attached to an antenna. The transponder can be packaged in many 
different ways. It can be mounted on a substrate to create a tag, or sandwiched between 
an adhesive layer and a paper label to create a printable RFID label, or smart label. 
Transponders can also be embedded in a plastic card, a key fob, the walls of a plastic 
container, and special packaging to resist heat, cold or harsh cleaning chemicals. The 
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form factor used depends on the application, but packaging the transponder adds 
significantly to the cost. 
Passive tags can operate at low frequency, high frequency and ultra-high frequency. 
Low-frequency systems generally operate at 124 kHz, 125 kHz or 135 kHz. High-
frequency systems use 13.56 MHz, and ultra-high frequency systems use a band 
anywhere from 860 MHz to 960 MHz. Some systems also use 2.45 Hz and other areas 
of the radio spectrum. 
Radio waves behave differently at each of these frequencies, which means the different 
frequencies are suitable for different applications. Low-frequency tags are ideal for 
applications where the tag needs to be read through material or water at close range 
(more about read range in a minute). As the frequency of radio waves is increased they 
start to behave more like light. They can't penetrate materials as well and tend to bounce 
off many objects. Waves in the UHF band are also absorbed by water. The big 
challenge facing companies using UHF systems is being able to read RFID tags on 
cases in the center of a pallet, or on materials made of metal or water. 
 
The absence of battery allows passive tags to be smaller, simpler, and less expensive, 
which makes it a natural upgrade from barcode, with the benefit of carrying more 
information about the tagged item. Active tags, however, are bulkier and more 
expensive. The active design is generally selected when other tag capabilities are 
desired, in addition to item identification. There are also semi-passive tag has a battery 
to operate the microchip, and also uses backscatter to communicate with the reader. 
Such tags have a considerably longer read range than passive tags [2].  
 
The cost of a passive tag depends on its frequency, the amount of memory, design of 
antenna and packaging around the transponder. The cost generally ranges from 20 cents 
for the simplest tags to several dollars for transponders embedded in a key fob or plastic 
housing, to protect the tag from heat, cold or chemicals. An RFID transponder ina 
thermal transfer label that can be used for printing bar codes is typically 40 cents or 
more.   
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1.2 Infrastructure Elements 
The RFID infrastructure consists of the elements that manage the devices and tag data. 
Consumers of the data are the client network elements (typically end-user applications). 
The network elements between the tag and the clients form the channel that transports 
tag data to the applications, and convey tag operational commands to the RFID devices. 
At a minimum, the RFID infrastructure comprises tags, readers, RNCs (Reader Network 
Controllers) and applications. In addition, other devices could also be in the network 
such as RFID/bar code readers, I/O devices (such as electric eyes, light stacks and 
actuators), bar code/smart label printers and applicators. 
Typically, a reader transmits an RF signal in the direction of a tag, which responds to 
the signal with another RF signal containing information identifying the item to which 
the tag is attached, and possibly other data. The tag may also include additional field-
writable memory store, and integrated transducers or environmental sensors for 
providing data such as the temperature or humidity of the environment. The reader 
receives the information and provides the tag data to the RNC which may do further 
processing before sending the data on to the applications (P. Krishna, 2007).  
 
The maximum range over which the reader can communicate with the tag depends on 
the transmit power of the reader, the environment through which the RF signal travels, 
the presence of interference and the receive sensitivity of the reader. Losses due to 
signal attenuation and multi-path interference reduce the range. Attenuation is low or 
negligible for gases in the atmosphere, such as nitrogen and oxygen, and also for paper, 
cardboard and certain plastics. Materials like metal and liquids have a stronger 
attenuating effect depending on their thickness. 
 
The Reader Network Controller (RNC) plays the role of the RFID infrastructure layer. 
It transforms a collection of autonomous readers and devices into a reliable and scalable 
network. RNC functionality includes real-time adaptive control and management of 
readers and devices, location-aware tag and sensor data processing.  
 
Infrastructure Functions  
The infrastructure comprises three interlocked communications paths:  
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− data processing (the Data path), that refers to the tag and sensor information 
collected by the readers and forwarded to the Reader Network Controller and 
applications; 
− device management (Management path): important because in an enterprise diverse 
types of devices are deployed; 
− device control and coordination (Control path): with the advent of sophisticated air-
protocols, and deployments of large number of readers, the need for reader control 
and coordination in the architecture becomes important. 
 
An RFID infrastructure must take in consideration: 
− Reader operations: A reader performs either inventory or access operations on a tag 
population. Inventory means that using a singulation algorithm, the reader isolates a 
single tag reply and reads the EPC memory contents from the tag. Access is used to 
describe the further operation of writing and/or reading other memory regions on a 
tag. Although the communication between a reader and tag is local, the interference 
impact due to that local communication is global; reader-to-reader interference 
occurs when a reader picks up another reader’s transmit signal at, or near, the same 
frequency. 
− Tag data processing: there is a phenomenon, which does not yet have a consistent 
name (it’s been called “unwanted reads”) and it is relates to the most fundamental 
difference between RFID and optical-bar-code technology (that it is replacing): the 
inability to know precisely which among the tags that a reader reads are the intended 
tags, and which are not. The optimal approach to eliminating unwanted reads is to 
rely on information such as the spatial relationships between the antennas and their 
locations, the read rates of the antennas, and the tags observed by the antennas. 
− Device management and monitoring: There may be little or no onsite IT support for 
networked RFID readers deployed in environments. In such situations, automated 
configuration and discovery of the RFID readers and devices as they are set up is 
essential. Once they are set up, RFID system administrators will need device 
management and monitoring tools, health and performance monitoring, and 
firmware management of the readers and other devices in the infrastructure, will be 
critical. 
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− Inter-enterprise and intra-enterprise tag data and event dissemination: The tag data 
collected and the business events generated by the infrastructure need to be 
disseminated for closed-loop, open-loop and cross-enterprise data collection. This 
data exchange can involve many processes and potentially many companies (P. 
Krishna, 2007). 
 
1.3 Middleware and Servers 
Middleware is a generic term used to describe software that resides between the RFID 
reader and enterprise applications. It's a critical component of any RFID system, 
because the middleware takes the raw data from the reader, filters it and passes on the 
useful event data to back-end systems. Middleware plays a key role in getting the right 
information to the right application at the right time. 
There are many RFID middleware products on the market. All do some basic filtering, 
but many also perform additional functions. Some middleware manages RFID readers: 
monitors their health, configures them, and sends software updates and so on. Some 
middleware has its own applications, often for a specific industry. One application 
might be confirmation of shipment and receipt. When a product is sent to a retailer, the 
middleware confirms the shipment and sends an electronic message to the retailer with 
the EPCs in the shipment. When the retailer receives the goods, receipt is confirmed and 
a message is sent to the supplier. The cost of middleware varies from vendor to vendor 
and is usually based on the number of locations where it will be installed, the 
complexity of the application and many other factors.  
Companies will also need to purchase servers to run middleware within a warehouse, 
distribution centre or production facility. These servers are sometimes called edge 
servers. Edge servers are standard computer servers. They typically do not have any 
special hardware, and they connect to readers using serial or USB ports [1].  
 
1.4 EPCglobal Network Infrastructure 
EPCglobal is leading the development of industry-driven standards for the Electronic 
Product Code (EPC) to support the use of Radio Frequency Identification (RFID) in 
today's networks. 
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The Electronic Product Code (EPC) is designed as a universal identifier that provides a 
unique identity for every physical object anywhere in the world, for all time. The 
canonical representation of an EPC is a Uniform Resource Identifier (URI). The 
EPCGlobal Tag Data Standard defines the structure of the URI syntax and binary 
format, as well as the encoding and decoding rules to allow conversion between these 
representations. EPC is not designed exclusively for use with RFID data carriers. The 
EPC is designed to meet the needs of various industries, while guaranteeing uniqueness 
for all EPC-compliant tags. 
 
The EPC Tag Data Standard defines the general data format for EPC number. In order 
to incorporate the globally accepted standards of all sectors, the EPC Tag Data Standard 
provides a structured, hierarchical numbering scheme in which the EPC is a numerical 
string comprised of several distinct segments.  Three of those segments, the EPC 
Manager Number, Object Class and Serial Number, are relevant to this discussion: 
− EPC Manager Number:  EPCglobal issues a unique identifier, called the EPC 
Manager Number, to each EPC Manager to identify that member within the 
EPCglobal Network, regardless of industry sector or geography.  The integration of 
the EPC Manager Number as a segment on the EPC string avoids fragmentation by 
enabling trading partners from any industry sector to be joined together in the 
EPCglobal Network. 
− Object Class: The Object Class segment identifies the type of product to which the 
EPC is attached (e.g., a bottle of medication). 
− Serial Number: The Serial Number segment identifies a specific instance of the 
object class (e.g. this specific bottle of medication).  In order to enable  EPC 
Managers to assign new EPCs without the possibility of collision with EPCs issued 
by other  EPC Managers, the EPC Tag Data Standard nests the Serial Number 
segment beneath the EPC Manager Number and Object Class (EPCglobal US 
COMMENT DHHS ANTI-COUNTERFEIT DRUG INITIATIVE WORKSHOP) . 
Figure 1: The structure of a 96-bit EPC (“Design and development of a mobile EPC-RFID-based self-validation system for 
product authentication”,S.K. Kwok, Jacky S.L. Ting, Albert H.C. Tsang, W.B. Lee, Benny C.F. Cheung, 2010).  
The AutoID Center, headquartered at MIT and working in conjunction with industry 
leaders and academic institutions around the world, designed a system for bringing the 
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benefits of RFID to the global supply chain. That system is referred to as the EPCglobal 
Network.  
The vision of the Auto-ID Center was to have a global network infrastructure, a layer 
integrated with the Internet that would enable companies to look up basic information 
about items as they moved through the global supply chain. Companies that want to 
take advantage of this open network will have to purchase servers to host local Object 
Name Service directories. ONS is similar to the Domain Name Service that points 
computers to Web sites. ONS will point computers to Internet databases where data 
associated with an EPC are stored. The ONS has a distributed architecture, like the 
DNS. But companies will want to host a local ONS to avoid having to go out to the 
Internet to look up information about products every time they read a tag. 
By using standards-based, EPCglobal-certified hardware and software components and 
interfaces, end users are assured that their EPC implementations and systems are 
compatible with their trading partners, enabling them to capture, store, and share EPC-
related data up and down the supply chain. 
The EPCglobal Network uses RFID technology to capture data and Internet technology 
to share and discover data. To capture EPC data, EPC tags carrying a globally unique 
EPC identifier are affixed to containers, pallets, cases, and/or individual units. Then, 
EPC readers at strategic points throughout the supply chain read each tag as it passes 
and communicate the EPC number with the time, date, and location of the read. That 
read event is then registered and stored at the local read site. Once the EPC data are 
captured, Internet technology is used to share that EPC data among authorised trading 
partners in the global supply chain. When a trading partner queries the network for 
information about an EPC, the query is directed to the location where information 
related to that EPC can be found. From there, various security services, including 
authorisation and access control, are performed before access is granted to the requested 
EPC information (Celeste Robert, 2006).  
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1.5 The frequencies used for communicating 
There is no global public body that governs the frequencies used for RFID. In principle, 
every country can set its own rules for this. 
Low-frequency (LF: 125–134.2 kHz and 140–148.5 kHz) (LowFID) tags and high-
frequency (HF: 13.56 MHz) (HighFID) tags can be used globally without a license. 
Ultra-high-frequency (UHF: 868–928 MHz) (Ultra-HighFID or UHFID) tags cannot be 
used globally as there is no single global standard. In North America, UHF can be used 
unlicensed for 902–928 MHz (±13 MHz from the 915 MHz center frequency), but 
restrictions exist for transmission power. In Europe, RFID and other low-power radio 
applications are regulated by ETSI recommendations, allowing RFID operation with 
somewhat complex band restrictions from 865–868 MHz. Readers are required to 
monitor a channel before transmitting ("Listen Before Talk"); this requirement has led 
to some restrictions on performance, the resolution of which is a subject of current 
research.  
In order to ensure global interoperability of products several organisations have setup 
additional standards for RFID testing. 
Among groups concerned with standardisation there is EPCglobal - this is the 
standardisation framework that is most likely to undergo International Standardisation 
according to ISO rules as with all sound standards in the world. Currently the big 
distributors and governmental customers are pushing EPC heavily as a standard well-
accepted in their community, but not yet regarded as for salvation to the rest of the 
world [9]. 
 
1.6 Application of RFID 
In 2010 three key factors drove a significant increase in RFID usage: decreased cost of 
equipment and tags, increased performance due to an higher level of reliability, a stable 
international standard around UHF passive RFID thanks to EPCglobal. 
RFID is becoming increasingly prevalent as the price of the technology decreases.  
This section has not the aim of illustrating all the possible application of RFID, but most 
of them and the most important and impactive. 
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1.6.1 Consumer Applications of RFID 
The most relevant applications of RFID in all-day life are the following [9]: 
− Electronic vehicle registration: with security of cars being a major concern in many 
countries, some countries are using RFID technology for vehicle registration and 
enforcement. RFID can help detect and retrieve stolen cars. RFID is also being used 
to secure assets. A transponder is embedded in the plastic housing around the base 
of the key. Keys for new cars also incorporate passive RFID tags that work with a 
reader near the car’s ignition switch. The reader will only accept codes stored in 
certain keys. If the code in a key does not match the reader in the car, the car will 
not start, making it more difficult to steal vehicles by copying keys. 
− Payment without contact: MasterCard and Visa are experimenting with RFID to 
give consumers the convenience of paying for small purchases with a wave of a 
contact-less smart card or key fob. These are a replacement for identification cards 
with magnetic stripes, providing a more reliable way to store identification 
information (magnetic stripes tend to wear out and lose information over time). 
RFID tags also have a higher memory capacity than magnetic stripes. 
− Payment by mobile phones: two credit card companies have developed specialised 
microSD cards. After inserting the microSD, a user's phone can be linked to bank 
accounts and used in mobile payment. For example, 7-Eleven has been working to 
promote a new touch-free payment system. Now, thanks to these applications, most 
phone manufacturers are creating phones with RFID capabilities: credit card 
information can be stored, and bank accounts can be directly accessed using the 
enabled handset. 
− Transportation payments: Public transit (bus, rail, subway). 
− Toll road. 
− Bicycle Parking Facilities: Some bike hirers are operated with RFID cards assigned 
to individual users. A prepaid card is required to open or enter a facility or locker 
and then used to track and charge based on how long the bike is parked. 
− Product tracking: RFID used in product tracking applications begins with plant-
based production processes, and then extends into post-sales configuration 
management policies for large buyers. RFID can also be used for supply chain 
management in the fashion industry. The RFID label is attached at the garment at 
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production, can be read/traced throughout the entire supply chain and is removed at 
the point of sale (POS) because of privacy concerns. 
− Animal identification. 
− Hospital and Healthcare: Adoption of RFID in the medical industry has been 
widespread and very effective. Hospitals are among the first users to combine both 
active and passive RFID technology. 
− Libraries: RFID tags used in libraries: square book tag, round CD/DVD tag and 
rectangular VHS. This technology has slowly begun to replace the traditional 
barcodes on library items, the RFID tag can contain identifying information, such as 
a book's title or material type, without having to be pointed to a separate database. 
The Dutch Union of Public Libraries is working on the concept of an interactive 
“context library”, where borrowers get a reader set, which leads them to the desired 
section of the library and which they can use to read information from books on the 
shelves with the desired level of detail, coming from the book's tag itself or a 
database elsewhere, and get tips on alternatives, based on the borrowers' 
preferences, thus creating a more personalised version of the library. 
− Passports: The first RFID passport (e-passport) were issued by Malaysia in 1998. In 
addition to information also contained on the visual data page of the passport, 
Malaysian e-passports record the travel history (time, date, and place) of entries and 
exits from the country. In 2006, RFID tags were included in new US Passport. 
− Schools and universities: School authorities in the Japanese cities are now chipping 
children's clothing, back packs, and student IDs in a primary school. A college in 
London, started September, 2008, is using an RFID card system to check in and out 
of the main gate, to both track attendance and prevent unauthorised entrance. 
− Museums: RFID technologies are now also implemented in end-user applications in 
museums. A visitor entering the museum receives an RF Tag that could be carried 
as a card, that enables the visitor to receive information about specific exhibits. 
− Ski resorts have adopted RFID tags to provide skiers hands-free access to ski lift. 
Skiers do not have to take their passes out of their pockets. 
− Human implants: Implantable RFID chips designed for animal tagging are now 
being used in humans. Security experts have warned against using RFID for 
authenticating people due to the risk of identity theft. 
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− Telemetry: Active RFID tags also have the potential to function as low-cost remote 
sensors that broadcast telemetry back to a base station. 
 
1.6.2 Industrial applications of RFID 
RFID applications are numerous and comprehensive. The most interesting and widely 
used industrial applications include those for asset tracking, supply chain management, 
manufacturing, security, movement tracking, product recalls and retailing (Geraldo 
Ferrer, 2010). 
 
Asset Tracking 
Companies can put RFID tags on assets that are lost or stolen often, that are under-
utilised or that are just hard to locate at the time they are needed.  
Logistics and transportation are major areas of implementation for RFID technology. 
For example, yard management, shipping and freight and distribution centres are some 
areas where RFID tracking technology is used. Transportation companies around the 
world value RFID technology due to its impact on the business value and efficiency. 
For example, a third-party logistics provider may need to track containers in its 
distribution centres.  
Air companies may need to track food carts used at airports around the world so to save 
great part of their expenditures: by placing active transponders under the carts and 
readers on the entrance and exits of catering facilities. They can not only loose fewer 
carts and spend less time and money taking inventory, they also are able to better 
manage the movement of carts.  
Another application is the baggage tracking, in the Hong Kong International Airport, 
the luggage is individually tagged with an RFID tags as they navigate the airport's 
baggage handling system, which improves efficiency and reduces misplaced items. 
 
Supply chain management 
RFID technology has been used in closed loop supply chains or to automate parts of the 
supply chain within a company's control for years. In supply chain management, RFID 
tags are used to track products throughout the supply chain: from supplier delivery, to 
warehouse stock and point of sale. 
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As standards emerge, companies are increasingly turning to RFID to track shipments 
among supply chain partners. New applications target tracking from checkout through 
customer billing. A central database records product movement, which manufacturers or 
retailers can later query for location, delivery confirmation. 
For this application, RFID basically serves as a replacement for the bar code scanners 
used to track products and shipments in similar ways. RFID is superior to bar codes for 
tracking inventory flow over the supply chain: 
− RFID does not require line-of-sight access to read the tag. 
− The read range of RFID is larger than that of a bar code reader. 
− Readers can simultaneously communicate with multiple RFID tags. Because of this 
capability, an RFID reader can capture the contents of an entire shipment as it is 
loaded into a warehouse or shipping container. A reader collects detail information 
in one pass, without having to scan each product. 
− Tags can store more data than bar codes. 
The last capability has several interesting applications in supply chain management. For 
example, read-write tags can store information about their environment. They can 
physically store their position and time throughout their movement in the supply chain. 
An example of a proposed use of RFID is to ensure safety in the supply chain. A US 
Food and Drug Administration (FDA) proposal supports using RFID to ensure the 
authenticity of prescription drugs. In this system, each drug shipment would carry a 
read-only RFID tag containing a unique serial number. Suppliers would track these 
serial numbers in shipment and have the drug purchaser verify the numbers on receipt, 
ensuring that the drugs came from where they were expected and arrived at their 
intended point of sale. 
Inventory systems 
A correlation to the supply chain management application is to enable automated just-
in-time product shipments. If all products in a retail store and associated warehouses 
have RFID tags, a store should have an accurate database of its inventory. Systems in 
retail outlets could automatically alert a warehouse management system that inventories 
are low. An advanced automatic identification technology based on the Radio 
Frequency Identification (RFID) technology has significant value for inventory systems. 
Notably, the technology provides an accurate knowledge of the current inventory. 
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At Wal-Mart, RFID reduced out of stocks by 30 percent for products selling between 
0.1 and 15 units a day. Other benefits of using RFID include the reduction of labor 
costs, the simplification of business processes, and the reduction of inventory 
inaccuracies.  
RFID combined with mobile computing and Web technologies provide a way for 
organisations to identify and manage their assets. Mobile computers, with integrated 
RFID readers, can now deliver a complete set of tools that eliminate paperwork, give 
proof of identification and attendance. This approach eliminates manual data entry. 
Web based management tools allow organisations to monitor their assets and make 
management decisions from anywhere in the world. Web based applications now mean 
that third parties, such as manufacturers and contractors can be granted access to update 
asset data, including for example, inspection history and transfer documentation online 
ensuring that the end user always has accurate, real-time data.  
 
Manufacturing 
RFID has been used in manufacturing plants for more than a decade. It's used to track 
parts and work in process and to reduce defects, increase throughput and manage the 
production of different versions of the same product. 
Boeing has been using an RFID system at it Wichita, Kansas, facility to track parts as 
they arrive, and as they move from one shop to another within the facility. In the past, 
bar codes associated with parts had to be scanned manually when a part went to an area 
in order to have a special chemical treatment. Then it had to be scanned out again. If a 
part wasn't scanned, the company lost track of it. Now RFID tags track the movement of 
parts automatically, reducing errors and the need to have people look for parts needed 
on the manufacturing line. 
 
Security 
RFID has long been used as an electronic key to control who has access to office 
buildings or areas within office buildings. Security and personal identification 
applications are a major and broad application of RFID. A common use of RFID is in 
identification cards to control building access. Many organisations use RFID tags 
embedded in ID cards, which are readable at a building entrance.  
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After the terrorist attacks on New York and Washington, D.C., in 2001, the U.S. 
Department of Transportation (DOT) conducted a number of tests of RFID seals to 
safeguard containers. Seals are active RFID tags that have a mechanism for sealing a 
container. If the container is opened without authorisation, that information is 
communicated to a computer the next time the RFID tag in the seal is read. Then, a 
warning can be sent and agents can check the container. 
 
Movement tracking 
Because moving objects can easily carry RFID tags, a common use is to track the 
movement of people and the information associated with them. Some hospitals now use 
tags, to ensure identification and to alert hospital staff should someone attempt to take 
the baby outside of the hospital without authorisation. Some schools are requiring 
children to wear tag-embedded bracelets or wrist bands while on school grounds, to 
monitor attendance and to locate lost children. The FDA recently approved a RFID tag 
that could stay with surgical patients in hospitals and store information on the surgical 
procedure the person requires, eliminating surprisingly common surgical mistakes. This 
application of RFID has obvious privacy issues. 
 
Product recalls 
One area of importance is product recalls. Today, companies often need to recall their 
products, (e.g., meat or drugs) if there is a problem to ensure people's safety. But they 
can never be sure they recovered all the bad goods that were released into the supply 
chain. With RFID, companies will be able to know exactly which items are bad and 
trace those through to stores. Customers that register their products could be contacted 
individually to ensure they know something they bought has been recalled. 
 
Retailing 
Retailers such as Tesco and Wal-Mart are in the forefront of RFID adoption. These 
retailers are currently focused on improving supply chain efficiency and making sure 
product is on the shelf when customers want to buy it. 
Metro in Germany and Tesco in the United Kingdom have done extensive testing to see 
if putting RFID tags on individual products in the store can will help them to reduce out 
 
 22 
of stocks. And Hewlett-Packard is tagging printers and electronic scanners shipped to 
Wal-Mart's Texas distribution centres. But given current tag costs (20 cents to 50 cents 
or more) it's likely to be several years before RFID has a big impact on retailing. 
Among the most talked about potential applications are the ability to automate the 
checkout process and eliminate lines and the ability to market to consumers who opt in 
to loyalty programs while they are making purchasing decisions. Experts envision 
people putting items into a shopping cart equipped with a computer, small display and 
RFID reader. When checking out, the consumer walks through a tunnel reader, has all 
the items in the car read automatically and pays with the swipe of contact-less credit 
card. These applications require tags to be on virtually all items in the store, something 
that won't happen for at least a decade [9]. 
 
1.7 Challenges and issues in RFID 
Even if this technology has a great impact on many applications, RFID is not without its 
challenges, which arise from both a technological and usage point of view. 
 
Privacy concerns 
A common concern with RFID is privacy. It is disconcerting for many people to have 
their movements or buying habits automatically tracked electronically. Many privacy 
groups are concerned about the ability to identify people as they walk through a store or 
shopping centre via the tags embedded in their clothing and linked to them at the time 
of purchase. 
To counter such concerns, RFID proponents propose that retail tags have “kill switches” 
that disable the tag at the point of sale. Even though a small tag might remain embedded 
inside a product, once the kill switch is activated, the tag would no longer transmit 
information. 
The read range of RFID tags is much too small to allow readers out of personal range to 
read tags carried on a person or in a vehicle, and materials, all around us, tend to absorb 
the relatively weak RF waves transmitted by passive tags, making it extremely difficult 
to pick up RFID signals through the walls of a home. However, privacy concerns are 
very real.  
 
 23 
Companies and government agencies must address these concerns before the public will 
truly feel comfortable using RFID systems. People will want to see policies about the 
use of an RFID system and the information it collects (Weinstein R., 2005). 
 
Security 
Security is another key issue in RFID. An organisation that implements RFID in its 
supply chain does not want competitors to track its shipments and inventory.  
People who use devices that carry personal financial information, such as credit card or 
other ID numbers, do not want others to access their accounts. These are significant 
security vulnerabilities in RFID. 
Some researchers have proposed schemes that would require tags to authenticate 
readers, transmitting information only to authorised readers. The tags would have to 
store ID numbers for authorised readers, and a reader would have to broadcast its ID to 
the tag (Weinstein R., 2005).  
 
Integration with legacy systems 
Another challenge to RFID is its integration into existing systems. Several vendors are 
developing RFID middleware that will link new RFID systems into existing back-end 
infrastructures. If an organisation picks a standard that changes or loses its market 
prevalence, middleware can transform the data from readers into the format supported 
by back-end systems. Middleware can provide the primary link between RFID readers 
and databases (Weinstein R., 2005). 
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2.  PHARMACEUTICAL SUPPLY CHAIN 
 
The aim of this chapter is to introduce the main components of the pharmaceutical 
supply chain and their principal features, then the section tries to synthesise the most 
important characteristics of the industry, and in the end the main problems faced by this 
industry are reported. 
 
2.1 Components of the pharmaceutical industry manufacturing 
and distribution chain 
The pharmaceutical supply chain is the means through which prescription medicines are 
delivered to patients. 
The pharmaceutical supply chain is different in its organisation from all the other kinds 
of supply chain. To start with, there are the big pharmaceutical companies who 
manufacture prescription drugs. Then the next stages in this distribution chain are the 
large wholesalers who buy in bulk quantities. They then supply these drugs at varying 
prices to big traders, regional distributors, national level pharmacy chains and large 
retailers like, as well as to hospitals.  
Between these entities, there are the large logistics service providers, warehousing 
companies and transporters who physically ship these drugs. Hence your corner 
pharmacy may have received its stock through at least two or three intermediaries with 
plenty of stops in between, where the drugs may be handled. Up to now, this is similar 
to the movement of consumer goods.  
This is where the similarity ends. For the pharmaceutical business, the pricing for each 
end user is different. Therefore a typical hospital gets these drugs at lower rates than 
does a corner pharmacy. The pharmaceutical supply system is complex, and involves 
multiple organisations that play differing but sometimes overlapping roles in drug 
distribution and contracting. This complexity results in considerable price variability 
across different types of consumers, and the supply chain is not well understood by 
patients or policymakers [10]. 
There are many variations on this basic structure, as the players in the supply chain are 
constantly evolving, and commercial relationships vary considerably by geography, 
type of medication, and other factors. 
 
 25 
A typical pharmaceutical supply chain will consist of the one or more of the following 
nodes (John V. Gray, 2011): 
− primary manufacturing (possibly including contractor sites); 
− secondary manufacturing (possibly including contractor sites); 
− market warehouses/distribution centres; 
− wholesalers; and 
− retailers (pharmacies)/hospitals. 
 
Figure 2: The main actors in the pharmaceutical supply chain (karbassi, 2009) 
 
2.1.1 Manufacturers 
Manufacturers are the source of the prescription drugs in the pharmaceutical supply 
chain. The pharmaceutical manufacturing industry is composed of two distinct business 
models: manufacturers of brand-name drugs (e.g., Pfizer, Merck, and Novartis) and 
manufacturers of generic drugs (Anonymous, 2005).  
There are few pharmaceutical companies that participate in both the branded and 
generic parts of the industry, and both models focus on the manufacturing and 
packaging of pharmaceutical products, but there are other important differences. Most 
brand manufacturers devote a portion of their expenses to the scientific research and 
development of new drug therapies. Generic drug manufacturers typically do not 
develop new drug therapies, but instead manufacture generic compounds, that compete 
directly with the original branded version of a drug once the brand product’s patent 
protection has expired. 
Manufacturers manage the actual distribution of drugs from manufacturing facilities to 
drug wholesalers, and in some cases, directly to retail pharmacy chains, mail-order and 
specialty pharmacies, hospital chains, and some health plans. Manufacturers may also 
distribute products directly to government purchasers, which typically receive the 
largest price discounts. Wholesale distributors are the manufacturers’ largest purchasers. 
Very few drugs are distributed directly to consumers. 
Manufacturers also play roles in stimulating demand for drug products: 
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− through underwriting clinical studies designed to demonstrate the value proposition 
of pharmaceutical treatments compared to one another or compared to no clinical 
treatment at all;  
− by engaging in the promotion and marketing of products to health care providers 
and direct-to-consumer advertising; and  
− by administering patient assistance programs that provide the firm’s products at 
nominal cost to low-income consumers. 
Manufacturers also play an important role in ensuring the safety of the pharmaceutical 
supply chain by producing informational labelling for prescribers and consumers , and 
by using electronic bar-coding technology on drug packaging that may be used to track 
individual production lots, and to prevent prescribing errors. 
 
Primary manufacturing 
The primary manufacturing site is responsible for the production of the active 
ingredient. This normally involves either several chemical synthesis and separation 
stages to build up the complex molecules involved, or fermentation and product 
recovery and purification in the case of biochemical processes (Shah Nilay, 2004). 
The manufacturing process is characterised by long task processing times, often 
rounded to multiples of shifts. Where multistage processes are operated, considerable 
inventories are often held between stages. Furthermore, material from an intermediate 
stage must often pass some form of quality control check before being approved for use 
downstream in the process. This can introduce additional delays into the system. 
The traditional process technology involves batch equipment and flexible pipework. 
The relatively low production volumes result in multipurpose plants to spread the 
capital cost between products. The need to avoid cross-contamination of products and 
requirements for validated cleaning and changeovers results in long downtimes between 
products. 
A further source of complexity (and convenience) is the use of contractors to 
manufacture some or indeed all of the active ingredient stages. This process of 
outsourcing is a growing one, as research-oriented companies concentrate on the 
discovery and development activities and rely on third parties’ manufacturing 
competence. This gives rise to extended supply chain co-ordination problems. 
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The production volumes are low, transportation costs are not significant at this stage of 
the supply chain, so primary sites may be located anywhere in the world, even distant 
from secondary manufacturers. The factors limiting the choice of location will be tax 
rates, existence of skilled working force, political and economic stability etc. 
 
Secondary manufacturing 
The secondary manufacturing is concerned with taking the active ingredient produced at 
the primary site and adding “excipient” materials along with further processing and 
packaging to produce the final products. An excipient is generally a pharmacologically 
inactive substance used as a carrier for the active ingredient of a medication. In many 
cases, an "active" substance may not be easily absorbed by the human body; in such 
cases the substance in question may be dissolved into or mixed with an excipient (Shah 
Nilay, 2004). 
For example, a product that is sold in pill form would undergo: 
(i) granulation: with addition of all the excipient materials;  
(ii) compression: forming the pills; 
(iii) coating;  
(iv) quality control; and 
(v) packaging. 
There are often many more secondary manufacturing sites than primary ones, serving 
local or regional markets. Transportation between sites is of the order of 1 or 2 weeks if 
by ship (usually the default mode) and of the order of one or two days if by air. 
Figure 3: The sequential phases of the serial production process. 
 
2.1.2 Wholesalers 
Wholesale distributors purchase pharmaceutical products from manufacturers and 
distribute them to a variety of customers, including pharmacies (retail and mail-order), 
hospitals, and long-term care and other medical facilities (e.g., community clinics, 
physician offices and diagnostic labs).  
Some wholesalers sell to a broad range of potential clients while others specialise in 
sales of particular products (e.g., biologic products) or sales to particular types of 
customers (e.g., nursing homes). 
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In the past, wholesalers limited their operations to a traditional distribution function. 
They provided the link between manufacturers and pharmacies by warehousing 
products and managing inventory. While “traditional” distribution services remain the 
cornerstone of the business, the industry has developed a more comprehensive list of 
services in response to the evolving marketplace, like: specialty drug distribution, drug 
repackaging, electronic order services, reimbursement support, and drug buy-back 
programs (Anonymous, 2005). 
 
Figure 4: The structure of the pharmaceutical supply chain. (RFID systems for pharmaceutical distributors to meet the new FDA 
regulations on drugs, Abhisam, Pharma 2020) 
 
 
Wholesalers play a significant role in this sector. They tend to be large and few. About 
80% of demand flows through this channel in the UK (with three large players 
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accounting for almost all the demand), with the large part of the remainder going to 
hospitals. The wholesale distribution industry has consolidated in the last 30 years, with 
the number of wholesale distributors in the U.S. declining from approximately 200 in 
1975 to fewer than 50 in 2000 (Shah Nilay, 2004). 
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2.1.3 Pharmacies 
Pharmacies are the final step on the pharmaceutical supply chain before drugs reach the 
consumer. Pharmacies purchase drugs from wholesalers, and occasionally directly from 
manufacturers, and then take physical possession of the drug products.  
After purchasing pharmaceuticals, pharmacies assume responsibility for their safe 
storage and dispensing to consumers.  
Pharmacy operations include: 
− maintaining an adequate stock of drug products, 
− providing information to consumers about the safe and effective use of prescription 
drugs, and 
− facilitating billing and payment for consumers participating in group health benefit 
plans. 
 
Pharmacies also serve as a vital information link between drug manufacturers, and 
wholesale distributors. Unlike most other sectors of the health care delivery system, the 
pharmaceutical supply chain is highly automated and virtually all claims transactions 
are handled electronically, rather than on paper. Pharmacies are not only as the final 
point of sale for pharmaceuticals, but also as an interface between the supply chain and 
the consumer. Because of this secondary function, they also generate information on 
prescription drug claims and health plans. Other types of information, both quality-
focused (e.g., drug-drug interaction warnings) and utilisation management-based (e.g., 
formulary compliance messaging) can originate from other parts of the supply chain, to 
the pharmacy as a prescription is being dispensed. As the final actor in the supply chain, 
it is up to the pharmacy to take action based on the information provided. 
There are several types of pharmacies, including independent pharmacies, chain drug 
stores, pharmacies in supermarkets and other large retail establishments, and mail-order 
pharmacies. Most pharmacies purchase their drug supply from a wholesale distributor, 
although in some cases, large institutional and retail chain pharmacies, specialty 
pharmacies, and mail-order pharmacies obtain drugs directly from a manufacturer. Once 
a pharmacy takes possession of the drug products, it distributes the products to 
physicians or directly to consumers. In addition, there are specialty pharmacies, which 
specialise in the distribution of high-cost and more complex drug therapies. 
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In addition to traditional retail pharmacy services, consumers have increasingly been 
using specialty and mail-order pharmacies over the past several years. Growth in the use 
of these types of pharmacies is expected to increase rapidly in the future. 
 
The main types of pharmacies are here listed, except for the traditional ones:  
− Specialty pharmacies serve patients with chronic diseases by dispensing high-cost 
biotechnology drugs. The specialty pharmacy industry today is dynamic, with new 
companies entering continuously. Types of firms in the market range from publicly-
traded stand-alone firms to retail pharmacies, and home health companies. 
− Mail-order pharmacies receive prescriptions by mail, fax, phone, or Internet at a 
central location; process the prescription in large, mostly automated centres; and 
mail the prescribed drugs back to the consumer.  
− Long-term care pharmacies, sometimes called institutional pharmacies, are a third 
type of specialised retail pharmacy. Long-term care pharmacies address the special 
needs of nursing homes, providing packaging for controlled administration, and 
special services that are more extensive than those provided by retail pharmacies., 
like: quality assurance checks, emergency drug kits and medication carts, regular 
and emergency (24-hour-a-day) delivery services, and in-service training programs 
for nurse aides, nurses, and other professional nursing facility staff (Anonymous, 
2005).  
 
2.2 Main features of the pharmaceutical supply chain 
In this section, a general overview of the pharmaceutical supply chain characteristics 
will be presented (Kamran Karbassi, 2009). 
Inside this supply chain it’s very important to get the product from the warehouse to the 
hospital as soon as possible, so the supply chain needs to be set accordingly to 
accommodate the need for the fast delivery of the product. In the pharmaceutical supply 
chain, this need for speed and delivery reliability is addressed by keeping excessive 
inventory at various warehouses.  
This is even more important because of the social responsibility that this industry has to 
ensure by providing 100% product availability at the right time at the right cost and in 
good conditions to right consumer. 
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There is a general trend for companies to divest excess capacity that came about from 
having many local manufacturing sites, and move towards a global supply chain 
management process. This brings with it many complex coordination issues and much 
tighter capacity constraints. Currently, the logistic cost in the sector is relatively high. 
 
In pharmaceutical supply chain, firms can gain flexibility by eliminating bottlenecks 
and having immediate access to advanced technologies; this would ensure 
responsiveness by meeting customer orders for special sizes, packaging or labelling and 
getting new product to the market as soon as they get approved. Therefore all the 
activities will need to be streamlined in order to gain the complete responsiveness and 
agility.  
 
Probably the single most important driver in the pharmaceutical industry is the time-to-
market. Companies secure very significant returns in the early life of a successful drug, 
before any competition. The competition-free life is shortening, typically from 5 to 1–2 
years. Competition in this sense relates to similar (rather than exactly the same) drugs. 
For most pharmaceutical companies it takes 10 to 15 years to introduce a new drug to 
the market so the earlier a product arrives to the market the more competition-free life 
the product will have. It is important to describe the life-cycle of a drug; it is somewhat 
different from that of other process industry products. 
The research or discovery phase tends to use thousands of more or less random test 
compounds against therapeutic targets. It typically takes about 10 years to result in a 
potential new drug that is registered. From this point onwards patent protection applies. 
The potential new drug must then be tested for both safety and efficacy.  
This involves a variety of trials: early on for toxicity and later on for ability to alleviate 
symptoms and remove disease. Finally, the process development activity comes up with 
a chemical or biochemical route to manufacture and an associated manufacturing 
process. This set of activities typically takes 6–8 years and is usually known as the 
development activity. 
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Figure 5: Pharmaceutical product life cycle(The TRIPs Agreement and pharmaceuticals, 2000).  
In pharmaceutical industry we have a push process from the manufacturing side, where 
the generic components would be manufactured according to the forecasts; instead on 
the other side, the process uses a pull strategy, because the national health service will 
be order from the pharmaceutical company according to the demand of the customers. 
 
Companies in pharmaceutical sector should share the necessary data with key vendors 
and customers in order to avoid the order loss, miss delivery and obsolete inventory, 
and so to ensure the visibility inside the whole supply chain. Another key issue for the 
visibility is the need for tracing drugs and product information in order to manage the 
full life-cycle of products. 
 
Anyway, the main issue of this industry is its regulations. Given the significant potential 
for adverse health effects, the industry is subject to very stringent regulations. This 
starts from the processes used to evaluate the safety and efficacy of the chemical 
compounds, through to the details of the process and plant design and manufacturing 
operations. It may be the case that the existence of regulatory protocols has hindered 
innovation in this sector; with companies blaming regulators for their own innate 
conservatism. 
The regulatory process tends to be slow and expensive; both these effects must be 
considered by the industry. Furthermore, the complex chemical compounds involved 
have more complex manufacturing processes, and the activities of route investigation, 
process development, scale-up plant design, commissioning and qualification are either 
increasing in duration. 
In pharmaceutical sector, so many regulatory bodies exist, affecting the supply chain 
and making this process very long and expensive. This is due to the high potential for 
adverse health effects and risk of fatality, so the government bodies need to influence 
this industry by controlling the patent issued, pricing the products, by controlling 
imports and exports, and by certifying the product and allowing the sales in the country. 
 
In recent past, this industry has been subjected to an high quantity of changes. Among 
all we can list these following (Shah Nilay, 2004): 
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− R&D productivity (in terms of numbers of new chemical entities registered per unit 
amount of investment) is declining; 
− effective patent lives are shortening;  
− even while active, patents provide lower barriers to entry;  
− there are many product substitutes in many therapeutic areas; either alternative 
compounds or off-patent generics; and  
− the payers of healthcare are exerting strong price pressure and influencing 
prescribing practices; this means that in order to be approved, new drugs must 
address new therapeutic areas or have very significant cost or health benefits over 
existing treatments. 
On the one hand, the global marketplace has become more liberalised, exposing 
products to competition. On the other, governments and other agencies have tended to 
intervene more as they become concerned at every increasing healthcare costs 
associated with ageing populations. Measures taken include strict controls on the prices 
of new drugs, more cost–benefit analysis, and encouragement of the use of generic 
substitutes or alternatives where possible. 
 
2.3 Problems and key issues inside the pharmaceutical supply 
chain 
Historically, most management attention has been paid to drug discovery and sales and 
marketing (the extreme ends of the supply chain), but now much more attention is being 
paid to supply chain optimisation as a means of delivering value. According to (Shah 
Nilay, 2004): 
− there is a welcome move away from viewing the supply chain as merely having to 
deliver security of supply at minimum cost, to a recognition of its ability to generate 
both value for the customer and hence to the shareholder; and 
− restructuring of the supply chain along regional and global lines will require 
massive reductions in capacity, which was acquired in many cases to propitiate 
national interest in return for sympathetic pricing. 
The main problems faced by this industry are now reported. 
 
2.3.1 Integrating the supply chain components 
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The supply chain components are primary sites (Active-Ingredient manufacturers) and 
respective storage facilities, secondary sites and respective warehouses and final 
product market areas. 
Each primary site may supply the active ingredient to any of the secondary sites and be 
located in any place around the world. For secondary sites and markets, we consider 
several geographical areas. Since transportation costs are very significant at this end of 
the supply chain, material flows between two different geographical areas are not 
allowed (Rui T. Sousa, 2011). 
 
It is relevant to make the following supply chain decisions: 
− where to allocate the manufacture of primary and secondary products and how to 
manage the available resources during the whole time horizon; 
− what production amounts and inventory levels should be set for each manufacturing 
site; 
− how to establish the product flows between primary and secondary sites and 
between secondary sites and markets. 
The company has to consider: 
− production costs;  
− transportation costs; 
− inventory handling costs; 
− products allocation costs;  
− unmet demand costs; 
− tax costs (Ruggero Golini, 2011). 
 
2.3.2 Information flows 
It is clear that pharmaceutical companies, positioned at the upstream part of health care 
value chain, have to carefully manage not only the upstream information flow, which 
carries demand data from the market, but also the downstream technical information 
flow, which helps creating demand (Marcelo Caldeira Pedroso, 2009).  
A first view on how those companies organise their supply chain shows that they have 
developed two different paths: one, a material delivering path, where products, order 
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information and financial assets are conveyed, and a demand creating path, where 
technical information on drugs is delivered to physicians. 
In the material delivering path, sell-in represents the product inflow to drugstores, and 
sell-out the product outflow to patients, which demand is generated by the physicians’ 
prescriptions. Drugstore inventories account for the difference between sell-in and sell-
out, and the ratio sell-in/sell-out for the effectiveness of inventory management of 
drugstores. Order information flows up-stream through the material delivering path, 
from customers to drugstores and eventually to pharmaceutical companies. Technical 
information flows downstream through the demand creating path, from pharmaceutical 
companies to physicians.  
Both information flows are complex, possessing particular features, and hard to 
manage. All pharmaceutical companies start delivering technical information to the 
market long before the product reaches drugstore shelves.   
As soon as a new molecule proves to be a potentially viable new commercial product 
and clinical trials reach the final stage (which can still take some years to be finished), 
pharmaceutical companies start working to build their technical information pipelines. 
Figure 6: Sell-in, sell-out and demand generation in the pharmaceutical industry (M.C. Pedroso, D. Nakano / Int. J. Production 
Economics 122, 2009). 
 
Pharmaceutical companies build multiple technical information pipelines. Since 
technical information is rich, and effectively delivering it implies interacting, discussing 
and clarifying questions. Rich information requires high capacity channels and it is 
much more effectively delivered by personal contact, so ICT-based systems play only a 
limited, supporting role.  
 
The characteristics that the information inside the pharmaceutical supply chain should 
have are (Yao-Hua Tan, 2010): 
− the information concerning the pharmaceutical product should flow with the product 
as the product moves through the supply chain and consumer environment; 
− this information needs to be freely available to those that require it; 
− this information needs to possess a high-level of integrity concerning its accuracy, 
and should only be able to be modified by authorised parties;  
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− lastly, this flow of information needs to be conducted in a manner that the privacy of 
all parties should be preserved and that the information should be provided to only 
those parties who are authorised for it. That is, any information that a consumer 
possesses drugs/medication can lead to discrimination. Consequently such 
information cannot be transmitted in public. If we use an RF signal to transmit 
information concerning pharmaceutical information then we must “hide it”. The 
solution is to encrypt this information. Only an authorised party should be able to 
determine the identity of a drug through the RF contact. Some relative information 
of a drug may also need to be protected due to commercial privacy. Usually 
manufacturers do not want others to know inside products and processes that they 
employ. 
Figure 7: Knowledge and information flows in pharmaceutical supply chain (M.C. Pedroso, D. Nakano / Int. J. Production 
Economics 122, 2009). 
 
2.3.3 Inventory control 
A pharmaceutical industry has the main objective of satisfying forecast demand for 
product end items by (Shawnee K. Vickery, 1985): 
− Minimising backorders (a customer order that cannot be filled when presented, and 
for which the customer is prepared to wait for some time) for the current scheduling 
horizon;  
− Minimising work-in-process and finished unit inventory levels; 
− Minimising work-in-process inventory accumulations. 
It is also important to reduce the cost of direct work inside the warehouse and speed up 
the inventory process. Most significant in the case of a pharmaceutical supply chain is 
to have a real-time inventory monitor within the manufacturing location, warehouse, 
and retail store.  
 
2.3.4 Contamination and substitution of both active and inactive 
ingredient within the global supply chain 
One trend in the pharmaceutical industry has been the global sourcing of both active 
and inactive ingredients from emerging economies where costs are lower. Further, the 
manufacture of generic drugs or those coming off patent are also more likely to be 
outsourced to manufacturers in developing countries (Ann Marucheck, 2011). For 
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example, in the last decade the value of India’s production of both active ingredients 
and finished formulations for export has doubled. The long supply chain, with sourcing, 
manufacturing, packaging and distribution occurring in different locations globally, has 
increased the risks of contamination or substitution of alternative ingredients.  
Risk control through governmental regulation and inspections may be ineffective in 
detecting all the risks that can occur at each point in a multi-tier supply chain, 
particularly when the contamination is intentional or when there is fraudulent 
certification that the product has met all regulations and passed inspection. 
 
2.3.5 Counterfeiting and infringement inside the supply chain 
Since the 1982 Tylenol deaths, public attention has been awakened to the vulnerability 
of pharmaceuticals in the supply chain (Ann Marucheck, 2011).  
Pharmaceuticals are chemical substances used to diagnose, cure, treat or prevent disease 
or adverse medical conditions. They are among the most highly regulated of all 
products with many nations enforcing strict regulations on the marketing and sale of 
drugs. Since they are metabolised in the body, pharmaceuticals are subject to many of 
the same regulations found in the food industry, in fact the government body that 
decides these norms in US is the Food and Drug Administration.  
However, since a drug must be proven safe and effective in fulfilling its intended 
medical purpose, the approval process contains additional controls such as medical and 
scientific review, as well as clinical patient trials, to empirically test its effectiveness 
within the population.  
In medicine and the life sciences, drug safety means efficacy of the treatment, the 
absence of serious side effects, and the minimisation of any interactions with other 
drugs that the patient may be taking. In the actual cases of contamination the fake drugs 
have contained ingredients that were (David C. Wyld, 2008): 
− inactive; 
− incorrect; 
− improperly dosed; 
− sub-potent; 
− super-potent; 
− expired; and/or 
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− contaminated. 
 
Given the complexity of the drug distribution system, achieving a closed distribution 
system is not an easy task. It has been estimated that there are approximately 80.000 
dispensing sites, only in the United States, that are supplied by a shifting group of 
primary and secondary wholesalers. While 3 major drug distributors dominate the 
primary market, there is a much larger number of both licensed primary and secondary 
distributors. 
Secondary buying and selling of packaged pharmaceuticals is common as a normal part 
of inventory adjustment; however, it is often the way in which counterfeit medicines 
have entered the US distribution system.  
In addition, numerous Internet sites offer consumers pharmaceuticals at deeply 
discounted prices even though these products are of dubious origin and quality.  
Repackaging of pharmaceuticals takes place at a variety of levels, removing the 
manufacturer’s original container/closure system and any incorporated counterfeit-
resistant features.  
Collectively, all of the above practices may create opportunities for counterfeit or 
diverted drugs to enter the system, thus potentially compromising the public health of 
patients. 
Companies already are beginning to employ counterfeit-resistant technologies into 
packaging and labelling for a number of products. Such technologies include overt and 
covert features incorporated into the packaging and/or labelling of the product and 
chemical tags incorporated into the drug product itself. Overt features include 
holographic images, special stickers, inks of gradated colours, or threads in the 
container label, all of which can be used to verify that the container is authentic. 
 
The main reasons of such an unfortunate growth in counterfeit drugs are (David C. 
Wyld, 2008):  
− the relative ease of it; 
− the cost of prescription drugs; 
− the web of country-specific regulations; 
− the vast cost disparities between countries on products; 
 
 40 
− the ease of transporting pharmaceuticals (which are generally shipped in cases, not 
pallets); 
− the practice of relabelling, repackaging, and reimporting controlled substances; 
− the low prospect of being caught once the counterfeit pharmaceuticals are integrated 
into the drug supply. 
The result is risk to patients’ health, either risk to their safety directly if the products are 
dangerous or risks from people suffering from complications from the many diseases 
that prescription drugs can treat today. 
 
There is already evidence that counterfeit drugs are worsening public health in general 
around the globe. For instance, in many Southeast Asian countries, over half the drugs 
sold do not have the correct formulation or levels of the active ingredient. Recently, the 
toll of counterfeit drugs is mounting worldwide. Consider these recent news headlines 
from around the globe: 
− Last year in Hamilton, Ontario, Canada, a registered pharmacist, was arrested by the 
Royal Canadian Mounted Police. He was working at a retail drug store, dispensed 
counterfeit doses of Norvasc to heart patients – pills filled with only talc. The local 
coroner investigated five patient deaths – all caused by a heart attack or stroke – that 
may have been brought about by the substitution of the counterfeit drug (Pitts, 
2005). 
− Within the last year, counterfeit versions of three popular drugs – Lipitor for 
cholesterol, Cialisw  and Reductil have surfaced in England. One British expert has 
estimated that 100,000 counterfeit drug imports are dispensed by the UK’s National 
Health Service annually (Eban, 2006). 
− In China, a counterfeit drug smuggling ring was recently broken-up that involved 
almost a half-million fake pills, including Lipitor. 
 
An important change, that contributes in the increase of counterfeiting phenomena is the 
increase of manufacturing outsourced activities, there are a number of unscrupulous 
manufacturers, many located in India, China and Southeast Asia, who will produce the 
counterfeit drugs and package them so they look authentic. Group purchasing 
organisations (GPOs) seeking lower costs for volume purchases may fall prey to 
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counterfeiters and bring them into hospitals and other health care organisations. Another 
source of counterfeiting includes hackers who breach the proprietary data of 
pharmaceutical corporations to steal formulas and logistics strategies. Finally, well-
publicised shortages of drugs, like vaccines, may cause legitimate health care 
organisations to seek alternatives to name brand products and unintentionally procure 
counterfeit drugs. 
 
Consequences of counterfeiting 
Counterfeit drugs cost pharmaceutical companies an estimated $46 billion annually. 
Considering the fact that pharmaceutical companies expend sometimes hundreds of 
millions of dollars to develop new drugs, this is a hit directly on their profits.  
Counterfeiters are able to offer a lower price point than the manufacturer and, therefore, 
pose an unfair competitive threat that can erode pharmaceutical company profits. 
Counterfeiting and other forms of intellectual property theft cost American businesses at 
least $250 billion annually and counterfeit drugs worldwide cost pharmaceutical 
companies as much as $46 billion annually. Moreover, industry metrics suggest that the 
counterfeit threat to profits is growing steadily (Alan Minsk, 2009).  
In 2007, the government estimated that United States spending on pharmaceuticals 
would surpass $247 billion in 2008. As consumer spending increases, so does the 
incentive for counterfeiters for entering in the legitimate market. 
Pharmaceutical companies also risk serious loss of consumer confidence as counterfeits 
become more prevalent, indeed the presence of counterfeit products in the market 
weakens legitimate brands, as when patients and doctors fail to see results from the use 
of what are unknowingly counterfeit products, they will be less likely to use or prescribe 
that brand of drug in the future. 
Increasingly, counterfeiters are dealing in drugs that are vital to consumer health, such 
as drugs for hypertension and high cholesterol. A counterfeit scare involving such vital 
drugs could substantially reduce consumer confidence in certain drug companies and 
brands of drugs. Companies that make large investments in developing their goodwill 
with consumers and establishing a trademarked brand name and image that inspires 
confidence must be proactive in protecting this substantial investment.  
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2.3.6 The rise of secondary distributors 
Another problem is the increasing number of secondary distributors; because of the 
complexity of the supply chain may grow. While not necessarily illegal, secondary 
distributors may present some safety risks. Secondary distributors represent another 
supply part in an already complex supply chain (Ann Marucheck, 2011).  
They often purchase product from a source other than the manufacturer, such as another 
distributor, and then sell the product directly to a health care organisation or a customer. 
Often when manufacturers offer discounts to meet sales targets or to reduce their 
inventories, secondary distributors may begin to stockpile drugs and later sell and divert 
them back into the primary distribution system.  
There are three possible safety problems related to this behaviour.  
− One is that secondary distributors may stock-pile drugs that are near their expiration 
date and then introduce them back into the supply chain at lower prices.  
− Second, the distributors may not have proper storage conditions for drugs that are 
sensitive to high temperatures and, thus, compromise the safety and effectiveness of 
the drug.  
− Third, the distributors may stock-pile critical drugs and, if the drug is in short 
supply, they will enter the market with inflated prices. While there may be nothing 
illegal with this arbitrage behaviour, it is certainly unethical. It also leads to 
conditions where counterfeiters could easily enter the market and infiltrate the 
primary supply chain by offering the critical drug at cheaper prices and in abundant 
supply. Thus, some of the challenges associated with balancing supply with demand 
in the pharmaceutical supply chain can be traced back to the influence of the 
secondary distributors. 
 
Because drug may be illicitly distributed like trafficking, a complete history 
(origination, transportation, distribution, usage and disposal) of a drug may be useful for 
tracing within a crime investigation. Each drug should have a reliable history record for 
lawful tracing. 
 
2.3.7 Recall 
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The supply chain is described not only by the traditional forward flow, that links 
suppliers to customers through factories, warehouses and distribution centres, but also 
considers the existence of reverse flows where recycling or non-conforming products 
are returned to factories, for extra processing, or sent to disposal (A.C.S. Amaro, 2008).  
As product recalls continue to increase, firms, regulators, investors, and consumers are 
gradually recognising that recalls are an inevitable part of conducting business. 
However, the recent spate of product recalls has shifted attention from why products are 
recalled to why it takes so long to recall a defective product that poses a potential safety 
hazard (Manpreet Hora, 2011).  
For example, in a recent and by this time famous automotive recall in the U.S., Toyota 
recalled many of its makes and models because their gas pedals were getting stuck, 
which clearly posed potentially serious safety hazards. 
Reduction of time to recall may be important for at least three reasons.  
− First, the sooner the defective product is recalled after it is first brought to market, 
the more the firm may benefit from learning about the defect and take rapid 
remedial action. Furthermore, it may be subsequently easier to fix similar defects in 
related products before they are sold and in turn potentially reduce further external 
failure costs. 
− Second, the recall effort and costs to withdraw the product will be lower if the 
recalled product is with the downstream supply chain intermediaries, such as a 
distributor or retailer, rather than in the hands of the end customers. As time to recall 
increases, so do the probability of additional defective product entering the 
marketplace, making recovery more challenging for the firm and thus increasing 
demand risk. For example, in 1982, Johnson & Johnson recalled 31 million units of 
Tylenol because of safety issues. 
− Third, as the time to recall defective and/or unsafe products lengthens, the delay 
may cause numerous injuries and even deaths. In those cases, questions begin to be 
raised by the stakeholders about the delay, and restoring the lost reputation becomes 
more challenging for firms.  
Processing recalls is a part of the reverse supply chain, as it requires logistical planning 
in order to take the product back and then dispose of it, repair it, or refund the purchase 
price. 
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The cumulative body of operations management research indicates a positive 
association between cost of good quality and performance. Firms adopting and 
implementing total quality management programs and winning quality awards show a 
positive association with both stock price and operating performance. Product recalls 
due to lack of safety highlight quality failures that can be expensive for the firm. 
The magnitude of a recall’s negative impact on performance varies by recall severity, 
firm size, and remedy to recall. Furthermore, costs of external failure are exacerbated if 
recalls related to lack of safety translate into incidents of product-harm crises such as 
injuries, deaths, and property damage - all of which may give rise to additional product 
liability charges linked reputation of firms with recalls and found that firms with a 
stronger reputation experience a higher reduction in their market value than do firms 
with a weaker reputation.  
 
2.3.8 The outsourcing trend 
Outsourcing has been defined by Chase et al. as an “act of moving some of a firm’s 
internal activities and decision responsibilities to outside providers”. Outsourcing is a 
broad phenomenon and it can cover many areas and industries. It’s based on the idea of 
focusing on core competencies, because it has been recognised in the strategy literature 
as a critical success factor in the long-term survival of a company (Youssef Boulaksil, 
2010). 
As companies have outsourced manufacturing to lower cost countries around the world, 
there has been concern that pressures for lower costs, combined with the additional 
complexity of the supply chain, will continue to lead to safety problems. 
An important issue is the relative benefits of vertical integration versus outsourcing with 
respect to safety. The high costs associated with supply disruption, product liability and 
potential recall might indicate that some low-cost suppliers are really high-cost 
suppliers when the expected costs of safety risk are considered.  
A second question is how to coordinate and monitor the behaviour of suppliers with 
respect to product safety. For example, in the case of the Mattel toy recall, the company 
had developed a certification program and rigorous testing rules to make sure that its 
Chinese contractors adhered to standards for the allowable levels of lead in paint. Yet 
some subcontractors were careless, while others intentionally violated the rules. 
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Information technologies are increasingly being explored as tools for better 
coordination and monitoring of the manufacturing process to avoid quality and safety 
problems. These technologies can provide real-time monitoring of processes across a 
global supply chain that allows companies to manage supplier behaviour, especially 
suppliers located across the globe. 
Even the FDA is taking a more collaborative approach and stressing education and 
training in its practices with foreign countries. Included in FDA’s budgets for fiscal year 
2010 were specific items designed to improve product quality and safety in the medical 
device industry. For example, it proposed to provide onsite training to foreign regulators 
on medical device safety and quality (Ann Marucheck, 2011). 
 
In the pharmaceutical industry, there has been the global sourcing of both active and 
inactive ingredients from emerging economies where costs are lower. Further, the 
manufacture of generic drugs or those coming off patent are also more likely to be 
outsourced to manufacturers in developing countries.  
The long supply chain, with sourcing, manufacturing, packaging and distribution 
occurring in different locations globally, has increased the risks of contamination or 
substitution of alternative ingredients, as in the case of the 2008 heparin accident. 
Sources of the counterfeiting problem are linked even with manufacturing outsourced: 
there are a number of unscrupulous manufacturers, many located in India, China and 
Southeast Asia, who will produce the counterfeit drugs and package them so they look 
authentic. 
Strategic outsourcing addresses the decision whether to outsource and several related 
issues such as the risks associated with outsourcing, the expected results of outsourcing, 
and conditions for successful outsourcing. Outsourcing on the operational level 
addresses issues that are relevant after having made the outsourcing decision, such as 
how to manage the outsourcing relationship, how much to outsource, and which orders 
to outsource.  
An outsourcing relationship can be more complex than a simple supplier-buyer 
relationship. The order process towards the contract manufacturers is complicated by 
the different connected decisions in time and the uncertainty of the available capacity 
from the contract manufacturer. Controlling a contract manufacturer operationally in the 
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same way as an internal manufacturing source leads to a nervous ordering behaviour 
with a lot of changes and a lot of panicky communication between the outsourcer and 
the contract manufacturer. It is essential to develop a more advanced order release 
mechanism that includes the various aspects of outsourcing, such as: capacity 
reservation, postponement, cancellation option, and the uncertain capacity allocation 
from the contract manufacturer. 
 
The pharmaceutical industry is facing increasing costs of developing new drugs while 
R&D productivity has stalled. In an effort to counteract this, pharmaceutical companies 
have outsourced work to third parties both in their home markets and offshore in 
emerging markets like India and China (Kate Kuhrt, 2008). 
Focusing on India, we can identify trends that are common at least within all the other 
countries among the so-called BRIC (Brazil, Russia, India and China) (Charles Conrad 
Uy, 2007). 
 
What the multinationals now seek from India is the same combination of brainpower 
and cost savings that made the subcontinent a leader in software and computer services. 
Some Western companies are volunteering to share intellectual property rights on new 
discoveries and even share the profits. The rush east, where five PhD chemists can be 
had for the cost of one in the West, entails risks. At a time when Pfizer, AstraZeneca, 
and others are cutting U.S. R&D jobs by the thousands, the build-up in Asia is bound to 
set off alarms that America is sacrificing another key industry through radical 
outsourcing. But if the strategy works, it could save the drug industry billions of dollars, 
bring down the prices of new drugs, and accelerate breakthroughs. 
Many Western executives say they're stunned at how quickly the Indian industry is 
achieving targets set by the joint ventures. Just a few decades ago, India was a outcast in 
the pharmaceutical business. New Delhi in the 1970s declared it would cease patents on 
Pharmaceuticals. Then thousand of generic drug-makers were born. The Indian 
executives argued they were providing a social service, selling antibiotics, say, for a 
fraction of what Western patent holders demanded. In the 1990s, Indian generics 
makers started selling AIDS cocktails in India and Africa at just $ l per dose. 
Even Indian drug executives, however, realised the imitation business was a dead end.  
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Almost all of India's top pharmaceutical managers recognise the only way to jump-start 
a modern industry is through collaboration with Western drug companies. So in 2003, 
New Delhi reversed course and said it would protect the rights of foreign patent holders. 
The first collaborations involved fairly simple lab work, mainly to save on labour costs. 
The Indians wanted more responsibility. 
Over time, the partnerships evolved into co-development arrangements. 
For the Western partners, the first objective in these alliances is to cut costs. In the U.S., 
specialised research outsourcing firms will charge a drug company $250,000 and up for 
the full-time services of a PhD chemist. With an Indian partner, the same work can be 
done for roughly one-fifth the cost. But what Western companies long for, more than 
anything, is to replenish their drug development pipelines. It can cost as much as $100 
million to develop a potential drug from a germ of an idea to the point where it is tested 
in people. After all that, the odds of any drug winning Food&Drug Administration 
approval are just 1 in 8. By conducting many experiments in low-cost Asia, the drug 
companies believe they can run more projects while keeping R&D budgets flat.  
Western drug companies are giving Asian partners more responsibilities than they ever 
imagined. SuvenLife Sciences, an Indian start-up in Hyderabad, is co-developing drugs 
for brain diseases with Lilly. As part of the deal, Suven can work on its own drugs for 
Alzheimer's, obesity, and Parkinson's disease, provided they don't compete with jointly 
developed products. Early on, Lilly sought to impose restrictions on Suven's own 
research. 
The benefits coming from the outsourcing of both drug manufacturing and research 
activities are relevant, but the pharmaceutical companies have to face a number of 
challenges. 
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3.  THE ANSWER OF RFID TO THE PHARMACEUTICAL-
INDUSTRY ISSUES 
 
After presenting the main characteristics of the RFID technology and the main fields of 
application and after introducing the parties involved in the pharmaceutical supply chain 
and the key features and issues faced by this industry, now in the third section of this 
work the aim is to understand how the RFID technology can provide solutions inside 
the pharmaceutical supply chain. 
In particular the chapter is structured to show first, how the RFID can perform for each 
of the problems presented in the previous chapter, then it presented a real case study 
reported by Kwock, Ting, Albert et al., and in the end, some guidelines to apply this 
technology inside the specific industry are provided. 
 
3.1 Counterfeiting 
As already said, companies are beginning to employ counterfeit-resistant technologies 
into packaging and labelling for a number of products, like: overt and covert features 
incorporated into the packaging and/or labelling of the product and chemical tags 
incorporated into the drug product itself (Goldhammer, 2006).  
Overt features include holographic images, special stickers, inks of gradated colours, or 
threads in the container label, all of which can be used to verify that the container is 
authentic. Some of these approaches are similar to technologies used for document 
authentication.  
Covert features include special inks, threads, or materials that are known only to the 
manufacturer and require special equipment (e.g., ultraviolet light source) to identify. 
Covert approaches also include the incorporation of small amounts of a chemical tag 
into the pharmaceutical preparation. Such chemicals can be part of the bulk formulation 
of active ingredient or incorporated into the gel capsule or film coating of the pill. The 
tag can be verified by chemical analysis by the company. Companies can also use the 
known analytical composition of the formulation for authentication purposes. For 
example, defined impurity profiles and/or amounts of different inactive ingredients as 
well as dissolution patterns can be tested to determine a drug’s authenticity. 
Counterfeit-resistant technologies serve 2 purposes, to: 
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− make more difficult and costly for counterfeiters to produce a convincing copy of a 
drug’s packaging and/or labelling and  
− provide companies a means for determining whether a questionable product is 
authentic or counterfeit.  
These are important goals, and the Pharmaceutical Research and Manufacturers of 
America (PhRMA) thus supports the use of counterfeit-resistant technologies on 
appropriate drug products. PhRMA believes it is critical to the success of anti-
counterfeiting strategies to erect as many hurdles as possible for the counterfeiters. 
At the same time, it is important to recognise the significant limitations of counterfeit-
resistant technologies.  
− First, these technologies are merely resistant to counterfeiting; they are not 
counterfeit proof. Experts believe that such features must be changed at regular 
interval as counterfeiters will reliably duplicate them. In fact, it is the experience of 
PhRMA member companies that even elaborate approaches such as holograms 
eventually are counterfeited and that any such feature must be rotated every 12 to 18 
months. 
− Another limitation with counterfeit-resistant technologies is that they do not provide 
real-time verification of a drug’s authenticity. Covert features and tags typically 
require specialised equipment or testing to authenticate and can and should be 
authenticated only by the manufacturer. These tests often cannot be performed on-
site or require a manufacturer’s representative to travel to the site. In addition, tests 
for tags may take up to several days to perform to accurately determine whether the 
drug is counterfeit. This may be problematic if a large amount of drug is of 
questionable authenticity as it would have to be withheld from commerce until the 
testing is completed. 
− Although overt features theoretically can be used for real-time verification, they are 
easier to counterfeit than covert features and thus provide the least assurance of 
authenticity. It simply is not realistic to expect pharmacists or patients to routinely 
check, or even be aware of, the wide variety of overt features used on the thousands 
of different drug products available through pharmacies. This problem will be 
exacerbated by the need to rotate overt features on a regular basis. 
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− Finally, overt and covert technologies are rendered useless if a drug product is 
repackaged, a practice that is common in the industry and subject to only minimal 
regulation.  
 
The US FDA advocates the adoption of track and trace technology and is promoting 
radio-frequency identification (RFID) technology that utilises an electronic product 
code (EPC) (Lybecker Kristina M., 2008).  
Drugstores are also making an effort to eliminate vulnerabilities in the supply chain and 
enhance safety. In 2002, the drugstore chain Eckerd notified its wholesalers that the 
company would discontinue buying from them if they ever provided counterfeit drugs 
to Eckerd. Moreover, CVS Corporation recently announced that it will no longer 
purchase drugs from wholesalers that trade in the secondary market, which has been a 
point of entry for counterfeit drugs into the supply chain. Through strategic contracting 
and supply restrictions, pharmaceutical manufacturers are also reigning in their 
wholesalers and distributors. In late 2003, Johnson & Johnson decided that it would no 
longer sell its products to US wholesalers that buy J&J products from other sources.  
Firm strategies extend beyond the traditional supply chain. According to a study 
conducted by Ernst & Young, drug-industry executives believe the Internet and mail-
order operations will be the biggest source of counterfeit drugs over the next five years. 
As such, firms are turning to unconventional allies with whom to partner in the battle 
against counterfeits. For example, Pfizer Inc. and Microsoft Corp. announced a joint 
effort to reduce Internet sales of Viagra. In another Internet-related effort, Google Inc. 
and Yahoo Inc., which account for two-thirds of all Internet searches, both decided to 
limit search-related pharmaceutical advertising in the US to licensed US and Canadian 
pharmacies. 
 
Even PhRMA member companies support the development of an electronic track-and-
trace system (using RFID chips for package identification) that can track drug products 
in real time throughout the distribution system (from manufacturer to patient) and 
provide an electronic pedigree for the authenticity of distributed drug products. 
Electronic track-and-trace technology will be a key element in strengthening the closed 
pharmaceutical distribution system. Before such a system can be implemented, 
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however, complex technological, legal, regulatory, and financial issues need to be 
resolved by all interested stakeholders (Goldhammer, 2006). 
The following schema outlines one approach for implementation: 
1. The manufacturer places a machine-readable serial number on the packaging. The 
minimum data elements are the serial number and a pointer to the database in which 
the necessary information to identify the specific pharmaceutical is contained. 
2. The first recipient of the packaged pharmaceutical electronically authenticates the 
serial number. A query to the database authenticates the number as being assigned 
to that particular package unit. The recipient’s business information and transaction 
date can be electronically recorded in the database. 
3. If a recipient of the pharmaceutical package does not authenticate the serial number 
according the above business practice, it will not be registered in the database. 
When the next recipient attempts to authenticate, the database query will respond 
with a message that the unit was not properly authenticated by the previous trading 
partner. Further distribution should cease until the cause for non-authentication is 
identified. 
4. The serial number is closed out at the point of dispensing. Subsequent queries to the 
database for that particular serial number will result in a response that it is non-
authentic. 
There still remains a significant amount of work that needs to be done to move toward 
an electronic drug authentication system.  
− Standards for mass serialisation must be finalised.  
− A proper assessment of the read failure must be done as implementation of the 
technology as described above argues for as close to a 100% success rate in reads 
for serialised pharmaceuticals. Product that cannot be authenticated will be 
presumed counterfeit unless other systems are in place. In addition, there will be a 
tremendous amount of validation activities that will be required for start up of these 
systems within manufacturing environments, requiring a high degree of assurance 
that they will perform as intended. There have been some reports that the read rate 
for RFID-tagged biologicals, liquids, and metal packaging fall well short of this 
goal.  
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− Business and data exchange practices must be put into place. The supply chain must 
be ready to embrace the technology in a timely manner.  
− In addition, the scope of products that will be mass serialised must be defined. 
− Consequently, while electronic track-and-trace processes are developing throughout 
the distribution chain with the building out of the necessary information systems, 
patients will be benefiting from the real-time authentication of drug-packaging units 
at the dispensing site. 
To move toward early adoption of electronic authentication, it is possible to propose the 
following steps: 
1. All package units of targeted prescription medicines should contain a machine-
readable serial number that includes the company identifier. The applicable package 
level to uniquely serialise includes the pallet, case, and item level. 
2. An appropriate information technology infrastructure should be constructed that will 
allow the dispensing site and other trusted parties to query through a central data 
portal. Data will be routed to the distributed database, where information on the 
package unit in question is kept. The dispensing site will receive a real-time signal 
back that the identification number is authentic for the product in question. 
3. Electronic authentication should focus initially on the end user dispensing site but is 
not intended to exclude other supply chain participants. Targeted pilots should also 
be undertaken by the pharmaceutical industry with the goal of furthering the 
development of electronic pedigrees. 
4. Operating rules must be established regarding the point and time of authentication. 
Following dispensing of the package unit (or the opening of a container containing 
multiple dispensing amounts), steps should be taken to prevent the subsequent 
illegal use of that unit’s serial number. 
5. Following successful demonstration of the viability of dispensing site 
authentication, this technology can be added to other partners in the supply chain, 
adding another tool to ensure authentic pharmaceutical product flow from the 
manufacturer to the end dispensing site. 
 
In addition to the actions above, the criminal penalties for counterfeiting prescription 
drug products must be significantly increased. For example, the current penalty under 
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the Federal Food, Drug, and Cosmetic Act does not reflect the serious public health 
risks associated with counterfeit drugs or serve as an adequate deterrent to prospective 
counterfeiters. PhRMA thus supports increasing the maximum criminal penalty for 
counterfeiting drug products from 3 to 20 years’ imprisonment. 
Finally, consumers also can play an important role in stopping counterfeits from 
entering the drug supply. They should purchase prescription drugs only from licensed 
US pharmacists. While a barrage of Internet pharmacy e-mails and Web sites promise 
low prices or access to certain drugs that are controlled substances, most of these are 
likely to be counterfeited. Internet pharmacies that display a verified Internet pharmacy 
practice sites (VIPPS) seal are licensed pharmacies through which FDA-approved 
medications can be purchased. These sites are identified by the VIPPS hyperlink seal 
displayed on the Web site.  
 
FDA departments all over the world are interested in knowing the correct identification 
of medicinal product, materials used in the preparation of medicinal products, 
equipment and the areas used for manufacturing etc. They require and demand 
documentary evidence for all these parameters; however at present they are not insisting 
on a particular technology to facilitate this process. RFID can be a good candidate to 
address this problem (Manohar Potdar, 2006). 
 
In the developing world counterfeit drugs are a major problem. Counterfeiters insert 
fakes at different points in the supply chain. They often sell directly to pharmacists, who 
think they're buying a discounted version of the real thing. According to the United 
Nations Office on Drugs and Crime, counterfeit drugs represent a $1.6 billion annual 
market in Africa and Asia alone. A handful of entrepreneurs are trying to make drug 
sales more reliable. Pharmasecure focuses on India. Aegate operates in Europe. And 
Sproxil, a mobile phone-based start-up in Boston, works in Nigeria. The founder 
decided to focus on Nigeria, because the Nigerian government is proactive about 
fighting counterfeit drugs, and Nigeria has a strong cell phone culture. Sproxil places 
scratch-off labels on bottles and blisters, instead of using RFID tags because of their 
high cost. When users scratch off the labels, they see a numerical code. They send that 
code, via text message, to a toll-free phone number, and immediately receive a text back 
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that indicates whether or not the drug is legit. The company makes money by selling the 
technology behind the scratch-offs to big pharmaceutical companies like Johnson & 
Johnson (Alberto Coustasse, 2010).  
 
3.2 Secondary distributors 
The grey market, the one made up by secondary wholesalers, is where the legitimate 
supply chain crumbles. An unauthorised source, using fraudulent pedigrees to sell 
tampered with or counterfeit drugs in legitimate channels of commerce, is where it 
becomes dangerous.  
For instance, a pharmacy believes it has purchased an authentic product from a 
wholesaler and the patient in turn believes he/she has purchased an authentic product. In 
fact, the origin is unknown or disguised and the safety and efficacy is compromised.  
Even in these situations RFID technology can play an important role, as is the case of 
the counterfeiting challenge [11]. 
 
The distributors may not have proper storage conditions: in fact for drugs that are 
sensitive to high temperatures and particular conditions can compromise the safety and 
effectiveness of the drug, we need to monitor the environmental conditions of the plant 
(Ann Marucheck, Noel Greis, 2011).  
However assuring high-quality products requires that the manufacturing facility is 
monitored 24/7 and this monitoring requires the use of high end networking technology. 
Currently pharmaceutical plants capture this information using a number of scalar 
sensors that measure temperature, pressure, humidity etc. In some developing nations 
this sensed information is manually recorded by a supervisor in charge. This often 
results in data entry errors that need to be addressed, an alternative can be to capture this 
information and process it in real time to provide the kind of track and trace useful to 
monitor the plant. The solution can be use a Wireless Sensor Networks, that is a 
network composed of intelligent embedded nodes capable of communicating over 
wireless link with base station and other nodes. Researchers are working on WSN for 
environment monitoring and for security check (Potdar M., 2009).  
 
The system comprising WSN network and RFID tags is shown in Fig. 8. 
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Figure 8: RFID-WSN Network Configuration (“Applications of Wireless Sensor Networks in Pharmaceutical Industry”, Manohar 
Potdar, Atif Sharif,Vidyasagar Potdar, Elizabeth Chang, 2009) 
 
 
3.3 Inventory and Warehousing Management 
The pharmaceutical industry handles different types of material and hence identity and 
stock management is a very crucial and important activity. The materials handled are 
classified in different categories and their identification and movement tracking is very 
essential for the management of the pharmaceutical unit and also a critical requirement 
of the FDA in every country (Manohar Potdar, 2006). Tracking of all such material is a 
big task and a challenge that RFID technology can address. There are two main areas in 
inventory management and control where RFID can be useful: 
− tracking entry and exit raw material and finished goods 
− smart shelving and smart search. 
 
Entry and exit tracking. 
RFID technology can have direct and useful applications in tracking the entry and exit 
of goods in a warehouse. All material entering the pharmaceutical manufacturing unit 
must be identified by the supplier name, manufacturer name, product name, batch 
numbers, quantity, dates of manufacturing and expiry etc. Other than that, there is a list 
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of certified vendors from which a particular material must be purchased. If each arriving 
container has a RFID tag to identify the suppliers or manufacturers, it would facilitate 
easier track and trace, at the same time it would help to certify that the material has 
arrived from the approved vendor. However, if this check fails then the material can be 
quarantined for further investigation.  
This test can be done at the entry site of the materials department or warehouse. This 
would prevent accidental use of the wrong category of materials, since FDA insist on 
use of tested and approved materials in manufacturing.  
RFID tags can help to validate the manufacturing and maintain quality control and 
quality assurance by documenting that only approved materials are being used. 
If RFID tags are fixed on transportable finished goods packs, it would facilitate the 
maintenance of automatic track and trace of all the materials leaving the manufacturing 
unit, which would further help in knowing and maintaining correct stock of all the 
finished product goods. 
 
Smart Shelf and Smart Search. 
Smart shelves are shelves that know what they carry, which means, they can be 
searched from a distant location and can offer the precise location of product or pallet. 
The capability to search the pallet location within the warehouse would save time and 
reduce the manpower associated with such administrative tasks, as well as facilitate 
decision-making. RFID technology can offer smart shelving and searching solutions. To 
do this all shelves in a warehouse should be first uniquely identified; this can be done 
using RFID tags. Each unique shelf location could then be used to associate it with a 
pallet. Hence, whenever a new consignment arrives at the warehouse, the RFID system 
can direct the consignment to the most appropriate location within the warehouse. Since 
the RFID system is capable to keep track of all the empty shelf space in the warehouse, 
the whole process can be automated. The whole warehouse can thus be operated from a 
remote location. The concept of smart can be further be extended to facilitate manual 
lookup, in large warehouse, it would be extremely beneficial if the exact location is 
highlighted by a LED or a bulb (pick-to-light system). Hence when a pallet is searched 
from a computing device the relevant LED would light up to exactly show the location 
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of the desired pallet. This would facilitate the warehouse operator to load and unload 
pallets then they enter or exit the warehouse. 
 
3.4 Integrating the supply chain components 
For the aim of integrating the supply chain components we need to gather a huge 
quantity of information inside the industry, because we need to take decisions about 
how to design our distribution channel and to set the level of inventory and the 
production capacity used by each plant.  
The information, that is necessary, is about the actual flow of products between each 
production site and the level of inventory present at the manufacturers in each moment 
during a period of time.  
Product ID authentication is enabled by assigning a globally unique serial number to 
each drug product, which distinguishes it from every other item of the same 
pharmaceutical product. Encoding the package of a pharmaceutical item with a unique 
identifier is known as serialisation. The serial number can be used to track and 
authenticate the product as the product moves through the supply chain, and so can 
provide the information required for designing and integrating our supply chain (S.K. 
Kwok, 2010). 
The authentication service provides a quick and easy method for wholesalers, 
pharmacies, and other dispensing end points to verify that the product serial number is 
authentic, that it originated from the pharmaceutical manufacturer, and that it is in a 
valid state (presumed to be safe) (Deus Lucia 2006).  
To enable a drug product for product ID authentication, a pharmaceutical company 
serialises each individual item, maintains a database of information about each item, 
and makes a service available for authorised downstream trading partners to query that 
database. 
Serial numbers can be applied to product packaging using RFID tags. As reported in the 
first chapter, EPCglobal has developed the electronic product code (EPC), a numbering 
format for the mass serialisation of items. 
The pharmaceutical company maintains a database of information about each serialised 
product that is enabled for authentication. The information can be used by downstream 
trading partners to establish that serial number was assigned by the pharmaceutical 
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company and that associated product information matches the physical product. The 
pharmaceutical company can make other product information available, including 
physical anti-counterfeiting measures, product status (such as recalled, stolen, and 
expired), and whether the product was in fact shipped. 
To allow downstream recipients of products to authenticate them, the pharmaceutical 
company makes a service available on the Internet such that recipients can query the 
database with serial numbers read from product packages. Results are returned to the 
downstream recipient in real time. The pharmaceutical company may make the 
authentication service available to these recipients or it may rely on third-party 
authentication services. 
An authentication service is typically a Web site that allows users to enter serial 
numbers and view the results of the query. Items may be authenticated at any point or at 
multiple points in the supply chain. A wholesaler may authenticate an entire pallet of 
items, and then a pharmacy may authenticate the same items individually when they are 
delivered. RFID technology accelerates the process when it is configured to collect and 
submit serial numbers for the query. 
The results of item authentication may notify pharmacists of recalled products or other 
safety concerns earlier, more reliably, and more consistently than other methods of 
communication. The authentication service may also provide guidance regarding 
physical anti-tampering measures and other safety features of the item packaging. 
The use of a pedigree to secure the distribution channel was introduced by state 
legislation, and to date, more than 10 US states have adopted pedigree legislation. As 
more and more states have adopted pedigree laws to secure drug distribution, 
technologies and standards for enabling secure electronic pedigrees have emerged in the 
marketplace. 
An electronic pedigree is a document that describes one or more pharmaceutical items 
and records the details of each transaction in which ownership of the items is 
transferred. 
Figure 9: It shows the RFID label applied to a drug package (“A counterfeit network analyzer based on RFID and EPC”, S.K. 
Kwok, S.L. Ting, Albert H.C. Tsang and C.F. Cheung, 2010). 
 
The pedigree records detailed information for each change-of-ownership transaction and 
the companies involved, including the business addresses, shipping addresses, 
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transaction identifier (such as purchase order or invoice number), transaction date, and 
quantity of items in the transaction. Finally, the pedigree includes a signature from the 
company certifying the information that is recorded on the pedigree about a transaction. 
In order to secure the transactions of its drugs in the distribution channel, the 
manufacturer initiates the electronic pedigree record and makes information describing 
the drug product and the sale transaction available. It then certifies the pedigree with a 
digital signature. When the drug moves through the supply chain, the pedigree is 
electronically transmitted to the receiving company. The pedigree system for the 
receiving company electronically authenticates the pedigree to verify the integrity of the 
signed transaction. For each subsequent sale in the supply chain, each company adds the 
new transaction details and certifies the pedigree with a digital signature and passes the 
pedigree to the next supply chain partner to be verified against the shipment. When 
implemented using commercially available technology and standards, the electronic 
pedigree offers security that functions at the scale and speed required by pharmaceutical 
supply chains. 
 
Figure 10: RFID-based Pharmaceutical Process (“RFID Application Framework for Pharmaceutical Supply Chain”, Dianmin Vue, 
Xiaodan Wu, Junbo Bai, 2008). 
 
 
RFID can play its tremendous advantages to help pharmaceutical supply chain to ensure 
not only its security but even to increase efficiency.  
RFID-based pharmaceutical manufacturing process, as is shown in Figure 10, is made 
up by different stages (Dianmin Yue, 2008): 
− when the pharmaceutical enterprise purchases raw materials, it requires suppliers tag 
raw materials in order to guarantee the safety of drugs and write the tag. The EPC 
information includes the supplier name, raw materials names, quantity, unit price, 
and other information. Manufacturer tests their warehouse, updates inventory 
records when materials check in. While the materials check out, the same task needs 
to be done; 
− during the manufacturing, because most of the materials are processing in pipes, the 
security is already guaranteed, so we don't tag them temporarily. We only scan and 
mark the materials when they enter into the pipes, control time efficiency, and 
package the products when they leave the pipes; 
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− packaging stage, first of all, manufacturer assigns a unique EPC number to each 
product. Packaging supplier writes the tags assigned by manufacturer and embeds 
the tag in empty packaging materials. The information includes drug name, number, 
production date, validity, effectiveness, etc. After the primary packaging of drugs, 
the product then proceed to level packaging, and increased information in order to 
track the drugs during shipping. 
 
In the process of tagging, with RFID technology and EPC, the main purpose is to make 
the information shared among pharmaceutical manufacturers, wholesalers, retail and 
hospital, they can track the drugs, in order to enhance the visibility.  
From the above analysis and design of view, RFID can be applied to the whole 
pharmaceutical processes: purchasing, manufacturing, packaging and delivering. During 
the process of RFID application, it can improve the efficiency of the pharmaceutical 
process, enhance the transparency of the pharmaceutical process to ensure drugs 
security in the manufacturing and transportation. 
 
If RFID technology is widely used in every stage in pharmaceutical supply chain 
including manufacturing, transportation, sales, usage and recall so on, pharmaceutical 
companies on the supply chain will share the information stored on RFID tags and can 
timely know the use of drugs, and then strengthen the efficiency of the whole system. 
 
A real example can help clarify these aspects.  
Today pharmaceutical companies are moving forward with these more comprehensive 
approaches and securing real drugs to protect patients.  
In January 2006, Pfizer began applying serialised RFID tags to all Viagra products sold 
in the United States. Pharmacies and wholesalers authenticate the EPC serial number on 
each bottle of Viagra and confirm that it is valid and was issued by Pfizer for that drug. 
More than 100.000 Viagra serial numbers have been authenticated by leading 
wholesalers and pharmacies, as well as smaller companies. Customers authenticating 
Viagra employ both high-velocity scanning techniques to check the product as it passes 
through normal warehouse operations and single serial number checks at pharmacies. 
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In addition to providing important consumer and brand protection, the program opens 
an efficient channel for managing communication of broad product issues that have 
previously been handled by thousands of e-mail and fax alerts. 
In order to take advantage of the extra layer of security, pharmacies will need to invest 
in RFID readers, which pick up the radio transmission from the RFID chip. The readers 
then communicate with Pfizer servers to verify the product code.  
Pfizer said it has invested several million dollars on the RFID project for Viagra. The 
application is not yet capable of tracking and tracing the pills throughout the supply 
chain, a capability that would require additional investments. Pfizer is exploring the 
possibility of implementing track and trace support in the future.  
Privacy advocates have cited concerns about the use of RFID in the supply chain for 
fear that the chips can track consumers' buying habits or transmit other personal 
information. Pfizer said that their chips are unlikely to travel home with consumers, 
though. Pharmacists typically dispense Viagra pills in quantities smaller than the 
amount that comes in a bottle from Pfizer, so it would be rare for a customer to end up 
with a bottle of Viagra with the RFID chip. 
Microchips are installed in drug-bearing pallets so shipments can be traced across the 
country. In some cases, even the individual bottles are tagged. Bottle tagging is more 
expensive, but it means that individual patients, or the thieves who stole their bottles, 
can be tracked. 
In 2006, there have been significant developments in regards to RFID tagging of 
prescription drugs.  
For Pfizer the decisions to move to RFID on these specific items were based on the 
popularity of these specific products, both in the mainstream and grey markets. All are 
amongst the leading counterfeited and diverted prescription drugs today (Deus Lucia 
2006).
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3.5 Information flows  
In pharmaceutical manufacturing operations many activities, areas, materials and 
documents are required to be handled by several people. Some of these are critical and 
confidential and hence not everyone is allowed to access them. This is required to 
maintain a level of secrecy and operational safety. One approach to address this issue is 
providing selective access. RFID technology may be used here to restrict access to 
authorised resources. There are different areas in the pharmaceutical industry, where 
RFID can be used for access control (Manohar Potdar, 2006). 
All pharmaceutical processes are required to be validated before they are used to 
manufacture a specific product. This shows that documentation plays a very important 
role in the pharmaceutical industry. Some examples of confidential documents include 
reports such as product development data, product stability data, technical audit, report 
of FDA, product recall and market complaints, etc. Document like these and several 
others are required to be handles with secrecy and confidentiality. These documents 
should be protected from being misused and intentionally corrupted. All critical 
documents must be clearly identifiable as original and genuine. Such documents have a 
separate physical area having restricted physical entry and selective access. RFID can 
be used for access control in two ways: to restrict human access high security area like 
this and to prevent movement of such documents in and out from these premises. 
All critical and confidential documents could be printed on RFID tagged papers. RFID 
tagged paper is similar to a normal paper, but has a barcode and a RFID chip 
underneath. It can be printed from RFID-enable printer. Hence using RFID can address 
the security issue with physical movement of confidential documents. 
 
As above mentioned, integration of RFID and EPC holds the promise of unprecedented 
supply chain visibility, so as to facilitate the information transmission among the supply 
chain parties. With correct implementation of such system in place, accurate and 
reliable supply chain information can be visualised for improving the whole system. It 
is expected that such integration is a promising approach to address the problems in 
pharmaceutical supply chain, especially the issue of insufficient information 
transmission (Ting S.L., 2010). 
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Each medicinal product is attached an EPC tag for identification purpose, for example a 
96-bit EPC tag has enough capacity for most applications. So the company can store not 
only information about the serial numbers of each product, but even the production date, 
manufacture information and shipment data. With the help of the automatic capturing 
capability of RFID, the product information can be updated from point to point, and 
users can even simply visualise particular product information by enquiring the unique 
identification code. Thus all the parties, from the manufacturers to the end customers, 
can be benefited by the implementation of this system (Alberto Coustasse, 2010). 
The self-developed EPC network supports more effective communication amongst the 
supply chain participants, enabling visualisation of hidden supply chain information. 
Through the adoption of RFID technology and the EPC standard, companies can view 
the life-cycle transactions of products on a user-friendly interface. All such information 
is stored in the centralised databases, closing the decision-making gaps between supply 
chain participants (S.K. Kwok, 2010). 
In particular important information about the level of inventories at the drugstores can 
be provided, in order to simplify the order information flow. 
Figure 11: The safe and secure supply chain model secures model secures both physical items and transaction records 
(“Technological Roles in Combating Drug Diversion and Counterfeiting” Lucia Deus, Journal of Pharmacy Practice, 2006). 
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3.6 Traceability and recalls 
Large global recalls associated with recent product safety events, for example the 
Chinese melamine-adulterated milk contamination in 2008, the adulterated Heparin in 
2008 and the Toyota recall of 2011, have made the development of tools and 
technologies for traceability through the supply chain a critical issue in risk control. For 
consumer products, traceability studies have addressed access to the supplier network 
for more immediate recall of products (Ann Marucheck, 2011).  
However, with respect to medical products, such as pharmaceuticals and medical 
devices, the ability to track and trace is critical to detecting if a product is counterfeit 
while also deterring intentional contamination, adulteration and diversion of legal 
products. This is an area where technology originally developed for tracking inventory 
and assets in the supply chain has proven to be very useful: an electronic pedigree 
which can provide information about the route of a product at the package level through 
the supply chain from manufacture to final use. Due to the special challenges in 
ensuring the safety of the pharmaceutical supply chain, recent legislation is requiring 
that all pharmaceuticals sold have an electronic pedigree or some unique product 
identification. In addition, to providing authentication of the product, these identifiers 
would provide critical information in the event of a recall. The ultimate goal is to have 
complete transparency of documents, information, and goods across borders. RFIDs are 
already considered a supply chain technology, but many consider them an inventory 
tracking tool that is used to address inaccurate inventory records. The use of RFID for 
tracking and tracing is still in its infancy, but it has great potential as the price of the 
tags declines and more companies adopt the technology. 
In the area of recall management, there are several unresolved questions related to risk 
discovery. They include identifying a product safety problem and mitigating the risk 
from a recall.  
One of the critical issues in identifying safety problems is the sharing of timely and 
accurate reporting of information regarding product reliability and malfunctions. Many 
companies lack the type of timely and complete information required to confidently 
make the decision to recall, however a delay in issuing a recall can lead to higher losses 
and risks more damage to the firm’s reputation. Companies may be wary of sharing 
information that they view as proprietary and possibly damaging. The bottleneck may 
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lie in having enough data and information to use these sophisticated information 
technologies in managing recalls. Operations management research, that addresses 
information sharing in collaborative supplier relationships, may provide insights to how 
product safety information can be collaboratively shared within an industry. 
A second question is how to best mitigate the risks and losses associated with a recall. 
Communication is a key element of an effective recall process. Speed of response is the 
most crucial variable to control the effects of risk.  
Product recalls and product counterfeiting are public safety issues. With improved 
visibility of supply chain information, companies can respond to public safety incidents 
more promptly and efficiently in identifying the products that need to be recalled and 
tracking the counterfeits. The proposed system effectively tracks products throughout 
the global supply networks, sharing product data for detection of counterfeited drugs in 
the supply chain. 
 
3.7 Outsourcing trend 
Another area that offers challenges for further research is the management of supply 
chain relationships. Many companies have outsourced manufacturing to lower cost 
countries around the world, because of the concerns about cost reduction, and so this 
phenomenon combined with the additional complexity of the supply chain will continue 
to lead to safety problems. 
A question is how to coordinate and monitor the behaviour of suppliers with respect to 
product safety. Information technologies are increasingly being explored as tools for 
better coordination and monitoring of the manufacturing process to avoid quality and 
safety problems, in particular RFID technology. Companies must invest time and effort 
in developing not only standards and principles of safety for their suppliers, but must 
also invest in education and training to build the skills and abilities within the supplier 
network to assure product safety.  
Another question is how to effectively educate suppliers. Even the FDA is taking a 
more collaborative approach and stressing education and training in its practices with 
foreign countries. Included in FDA’s budgets for fiscal year 2010 were specific items 
designed to improve product quality and safety in the medical device industry. For 
example, it proposed to provide onsite training to foreign regulators on medical device 
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safety and quality. Also, it proposed to develop supplier relationships that promote and 
provide incentives for safety with suppliers, including the implementation of cost-
sharing contracts for recalls.  
 
3.8 An example of RFID application in the pharmaceutical 
industry 
A significant example is provided by Kwock, Ting, Albert et al. in “A counterfeit 
network analyser based on RFID and EPC”, in which they present the example of a 
Chinese pharmaceutical company Harmonic that decided to apply the counterfeit 
network analyser inside its supply chain. 
A counterfeit network analyser (CNA) integrates the automatic data capture technology 
(RFID), information sharing network (EPC network), higher security measure, and 
social network analysis concept. It is designed to perform three functions that include 
automatic product identification, encryption and decryption, and intelligent detection of 
the counterfeit source. The automatic product identification function refers to 
continuous monitoring of the condition of pedigree information. Through the encryption 
and decryption function, the information shared and uploaded in the EPC network can 
be enhanced to a higher level of security. On the other hand, the intelligent counterfeit-
source detector is used to discover a potential counterfeiter within the authorised supply 
chain by computing the emission level of the counterfeits. 
Harmonic Health Pharmaceutical Co. develops health foods and beauty products 
extracted and purified from pure Chinese medicines. The company’s health food series 
have been selling in the market since 1999, and the company has been a pioneer in the 
production of Chinese medicine capsule pills. Over the years, these pills established a 
good reputation in Hong Kong, but this has also attracted the attention of counterfeiters, 
causing subsequent loss of business and damage to the goodwill of the company. 
Harmonic has modified the packaging design of these products four times in the last 
two years with the aim of differentiating its genuine products from the fakes.  
Owing to the fact that the original packages were found to be counterfeited very 
quickly, the company suffered from potential business risk which adversely affects the 
business operations of the company. Moreover, Harmonic needs to distribute the 
products around the world and many activities would take place at each intermediate 
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point in the supply chain. To avoid any counterfeiting behaviour existing in these 
intermediate points, the company requires the supply chain party at each immediate 
point to manually record the information in Harmonic’s single standalone database via a 
web-based system. However, such approaches have suffered from human error and 
many parties are not willing to update the data in the system. Owing to the potential 
drug hazard (as the drug can be changed or counterfeited easily), the lack of visibility of 
the product flow, and the expensive repackage design, Harmonic decided to apply the 
CNA. 
Figure 12: Conceptual framework of the information flows between the proposed supply chain network and stakeholders (“A 
counterfeit network analyzer based on RFID and EPC”, S.K. Kwok, S.L. Ting, Albert H.C. Tsang and C.F. Cheung, 2010). 
 
In order to set up an RFID environment, Harmonic and its authorised parties in the 
distribution channel are required to adopt the following prerequisites: 
− Harmonic has to apply a range of universal unique EPCs from the industry-driven 
standard and encode the EPC information into each product’s RFID tag, hence 
encoding the product information in each RFID tag that is compatible with the EPC 
standard. 
− Companies in the supply chain need to register with the EPC network and install an 
RFID reader to capture the RFID signals. 
− A data warehouse is established in each supply chain party for storing the 
transaction data, in which it can be accomplished by setting up a database system. 
− Harmonic needs to define the product flow in the supply chain, by considering what 
information should be captured and  who can access the information. 
 
The tag was placed inside the package to prevent people from removing the tag (see 
figure at page 60). Furthermore, the box was sealed with a security label sticker (with 
company name) to protect it from being transferred by unauthorised parties. All these 
security measures helped to minimise the problem of unauthorised tag removal. 
The RFID reader was able to simultaneously record 500 tags with an average reading 
time of a second. It can correctly read tags with an accuracy of 100 percentage when 
there are less than 100 tags scanned in one time. Therefore, it is designed to enable 50 
packages to be put into a big box when they are shipped and delivered to other parties. 
The results of the tests indicate that there is about a 1 percentage error rate due to the 
reading conflict, and two readings were required to detect all the tags correctly. 
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Each healthcare product is first tagged by RFID at the manufacturing site, thereby 
providing detailed information on the product. Every party in the supply chain network 
(i.e. from manufacturer to retailer) is equipped with RFID readers to register the point-
to-point transactions of the products.  
Compared with the current manual operation in the collection of supply chain 
information, RFID demonstrates its automatic feature for data acquisition, which 
enables an end-to-end supply chain visibility with high accuracy. With the high 
readability and accuracy of the RFID, the unwillingness or incorrect human input can be 
greatly reduced when CNA is adopted. As a result, Harmonic is able to search and 
retrieve the product’s supply chain transactions and the history of a specific product 
movement from the EPC network. 
The CNA not only enhances the effectiveness of product authentication, but also 
estimates the possibility of a counterfeit source based on the use of social network 
analysis. It enables users to monitor and detect the counterfeit source distribution via a 
standard browser. Aggregation of all problematic ePedigree provides important 
information for Harmonic to estimate which supply chain party is problematic. The 
detection is accomplished by the social network analysis, a graphical representation. 
The likelihood of a party being a counterfeit source is colour coded for ease of 
interpretation. A node with a lower possibility is denoted in light yellow colour and the 
colour changes gradually such that a node with the highest possibility is shown in dark 
red colour. Based on the graphical result, Harmonic can identify the questionable parties 
and scrutinise such intermediate problem areas. Mainly, the system fully captures the 
product flow data across all the intermediate points. 
Owing to the complexity of the Harmonic supply chain network, it is difficult to 
monitor where the counterfeit originates. Consequently, these counterfeit drugs not only 
threat public health but also lead a loss of sales and reputation, as customers may feel 
less confident in purchasing the products. To cope with these problems, the supply 
chain information visibility featured in CNA has helped Harmonic to discover the 
counterfeiting some as well as improving the company image by selling genuine drugs.  
 
 
 69 
3.9 Guidelines for applying RFID in the pharmaceutical 
industry 
Because of the generally higher per unit values of the products that they make and 
distribute, pharmaceutical manufacturers and distributors have the luxury of not being 
as cost-centric about RFID technology (particularly tag costs) as consumer product 
companies. While tag costs are certainly critical, they should not be the singular focus 
of companies that wish to achieve the maximum Return On Investment (ROI) from 
RFID technology (Vivek Bapat, 2005).  
Additionally, pharmaceutical companies cannot look at RFID from a purely traditional 
ROI perspective, but have to consider the potential economic consequences of not 
applying RFID technology to a single drug whose credibility and sales are compromised 
due to widespread counterfeiting. 
There will be a minimal ROI in the near-term, but in the long term, RFID is the right 
approach for product authentication and creation of an electronic pedigree through the 
supply chain. There are significant benefits in pharmaceutical industry in identifying 
product from the point of manufacture to the retail pharmacy and in sharing and make 
the information visible up and down the supply chain. 
Despite advances with RFID, several issues need to be resolved before widespread 
adoption is possible. Without established standards, many companies are reluctant to 
invest in the technology. Furthermore, the implementation of RFID technology affects 
many different areas of a business and can become quite costly to execute.  
A critical piece to the puzzle is the development of standards around data exchange, 
numbering schemes, and tag frequencies.  
Additionally, there is the cost factor. Although the price of tags has come down over the 
past year, implementation of the technology as a whole remains expensive (30-35 cents 
a tag per unit) [11]. 
It takes a cross-functional effort to implement RFID technology and a lot of dedicated 
resources because it isn’t an off-the-shelf technology. Implementing the technology 
involves many different functions within a pharmaceutical organisation because it is 
such a highly regulated business. 
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While the industry sees the need to implement anti-counterfeiting technologies, many 
companies are also waiting for anti-counterfeit products to be commercialised by others 
before implementing the solutions for their drug products. 
 
For years, manufacturers have invested in ways to link production with supply chain 
information to not only optimise inventory, but also to improve production efficiency, 
flexibility, and responsiveness. For these manufacturers, a combination of RFID 
investments can quickly and cost-effectively deliver functionality (Vivek Bapat, 2005).   
For optimal RFID success, efforts to improve inventory visibility across the supply 
chain should be closely tied to a company's control systems and execution processes 
driving production. 
By applying RFID technology incrementally across the plant floor, manufacturers can 
seamlessly integrate the new information captured by RFID, without disruption, into 
existing, proven, industrially hardened control, visualisation and information 
infrastructure, reducing the need for purchasing new infrastructure or investing in 
expensive, time-consuming, and unproven IT integration projects. Existing 
manufacturing execution and information systems can then be updated to deliver robust 
and reliable real-time information flow to drive manufacturing execution in tune with 
the RFID-enabled supply chain.  
Manufacturers are increasingly learning the importance of designing and integrating 
RFID information and solving connectivity issues related to plant floor and 
warehousing execution so that the new information is integrated into the plant floor 
reliably and through industrially hardened conduits.  
Some guidelines about how to apply RFID inside the supply chain follow. These 
guidelines can be easily used and extended at the case of pharmaceutical industry. 
1. Business Case Justification and ROI Analysis  
This first step includes helping a manufacturer develop a complete ROI analysis to 
support budgetary needs and investment outlays across the entire supply chain. The ROI 
analysis will address numerous business issues:  
− Where will the production and service disruption be minimal, but the returns the 
fastest?  
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− What incremental investments will be needed as part of a long-term strategy, and 
during what time frame?  
− By conducting simulations and pilot programs, manufacturers can better understand 
the ROI of their potential RFID investment.  
2. Design and Architecture  
In this step, manufacturers can select tags and readers that are most suited to their 
environments, provide piloting assistance related to RFID laboratories, set up mobile 
labs for testing in the customers' environments, and arrange lab tours at existing internal 
or customer sites. Additionally, manufacturers can design an integration strategy with 
their existing bar-code implementations and a methodology to integrate their RFID 
information into their ERP systems, including providing case-to-pallet validation at 
end-of-line operations.  
Another important aspect of this step involves helping manufacturers reliably and cost-
effectively synchronise their RFID information with their control systems; help them 
design process and automation capabilities to facilitate item-level tracking and tracing 
functionality.  
3. Software and Systems Integration  
In this step, manufacturers can comprehensively integrate their RFID implementations 
into mainstream manufacturing and warehousing operation, from the ERP level to the 
control level. This step also includes integration with middleware and integration with 
local database management systems, ERP systems and control systems.  
4. Maintenance and Support  
An RFID project doesn't stop after it is implemented. There is an ongoing process of 
maintenance and support to ensure that all aspects of the RFID implementation are 
continuously monitored and supported at an engineering level, as well as from an 
information service perspective.  
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The RFID Adoption Cycle   
Although companies can gain significant business value by deploying RFID 
technology, a supplier can't simply slap a smart label - one with an RFID tag embedded 
in it - on cases, stack the cases randomly on a pallet, and expect to accurately read every 
tag. 
Suppliers must resolve several production-related issues before applying RFID for 
tagging product. For example, products with high liquid content or containing metal (in 
the product or its packaging) require special consideration since liquids and metals can 
distort or impede RFID radio waves. Potential solutions might include using a specific 
type of tag, placing the tag in a precise location on the case, or arranging the cases in a 
special configuration on a pallet. Many companies are learning through trial and error. 
According to several industry analyst groups, the RFID adoption cycle for most 
manufacturers typically progresses from pallet-level tagging to tagging individual 
products. 
Leading manufacturers are quickly investigating and adopting RFID initiatives from 
both short-term and long-term strategic perspectives. This is being accomplished in a 
two-phased approach, summarised as follows:  
Phase I: Tag Application  
This phase predominantly consists of closed-loop piloting activity that is internally 
managed through pilot teams consisting of engineering, warehousing, IT, and plant 
managers. Phase I activity examples include devising solutions that trace products at the 
pallet level and matching the information to a production order. For manufacturers, the 
main issues in this phase revolve around validating tags, checking errors, and 
comparing the reliability standards of RFID to those of bar code technology.  
Phase II: RFID Deployed as an Integral Part of Operations and to Gain Strategic 
Advantage  
This phase includes tactical and execution plans surrounding increasing levels of 
integration of RFID deployment into mainstream business operations. As part of this 
phase, manufacturers ask key questions such as:  
− How far downstream into manufacturing and out into the supply chain should RFID 
be implemented? 
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− How far upstream and at what level of granularity and into the production process 
should RFID be implemented? 
− Which types of standards, software, and integration should be deployed?  
 
For pharmaceutical manufacturers seeking to better manage inventory and more rapidly 
conduct recalls and reduce counterfeiting, theft, and shrinkage, RFID technology is 
clearly superior to any other competing alternative.  
Companies in this industry would be wise to think about the potential benefits of RFID 
far beyond just a ROI equation; the potential consequences of not applying this 
technology are too large. Instead, companies should look to and learn from the RFID 
success examples provided by others within their industry, work incrementally with the 
right strategic partners to add RFID technology to their own operations, and begin to 
enjoy the innumerable benefits which RFID technology promises.  
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3.10 Discussion 
The main problems faced by the pharmaceutical supply chain and presented previously 
in this work, can be solved and addressed properly by using and integrating RFID with 
the technology already in use inside the industry. 
For what concerns the main and more dangerous problem, that is counterfeiting, the 
traditional overt and covert solutions used in order to avoid it are not able to totally 
protect medicines from people that try to break into the supply chain in order to make 
drugs become inactive or incorrect, or sub/super-potent. Indeed these solutions do not 
give any proof of the counterfeit identification, but they try to be resistant to 
counterfeiters; instead RFID is able to make more difficult to enter in the supply chain, 
by storing information about each party involved in the industry, and by integrating all 
the members in a unique information system. Each member of the industry will store its 
information in the tag and check if the previous stored data are reliable or not. 
This technology is able even to identify in which part there is a slack or a break, so 
which party is the counterfeiter. 
The recall process is linked to counterfeiting; when a batch of product is identified as 
not legit so it is needed to recall it before it reaches the market by causing possible 
damages to the population. First of all, there is the need to identify where the batch is, 
and so the track and trace system may be really useful for this purpose.  
To best mitigate the risks and losses associated with a recall, communication is a key 
element that helps to improve the visibility and to respond to public safety issues more 
rapidly. 
RFID can control the storage condition of the products, in particular for those that 
require certain level of humidity or temperature to be preserved. So the integration of 
RFID system inside a Wireless Sensor Network may be capable to monitor the plants, 
so that a lower number of employees may be occupied by automating this control. 
The efficiency of the industry may improve by using RFID to manage the inventory 
system, so that it is possible to track and trace the products that enter inside the plant 
and those who exit from it. The system can provide accurate knowledge of the current 
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level of inventory, in order to avoid the stock out of the material, that is a critical point 
of success for this trade. 
RFID may be even used for managing the information flows not only about the 
transaction between the trade partners, but even secret information about product 
development data, technical audit, report of FDA, product recall in order to prevent 
movement of such documents in and out without permission. 
The advantage of this technology is the supply chain visibility provided that assures 
more effective communication and collaboration among the involved parties. 
Particularly important is the possibility to share information about the level of 
inventories at each stage so that it will be possible to make the ordering flow easier. 
This capacity is especially important in this sector because of the outsourcing trend that 
requires manufacturers to manage supply chain relationship in a proactive way by 
avoiding safety and quality issues. 
 
The global advantages provided by this technology are: 
− lower costs due to the avoidance of the loss of image and loss of money for the 
recall of product identified as counterfeited more downstream; 
− the capacity to identify the point of the supply chain where the counterfeiter breaks 
inside it; 
− the origin and authenticity of the product is secured;  
− higher visibility of the supply chain and of all the component behaviour; 
− higher level of quality for the product thanks to the monitoring 24/7 by the WSN; 
− the improved communication among participants; 
− higher level of efficiency in managing the inventory at each step of the supply 
chain;  
− significantly reduce cost and time required for physical inventory: the time it takes 
to do physical inventory is reduced by 90% from several man-days to a fraction of a 
day; 
− management could reduce monthly inventory level; 
− the resulting RFID-based inventory will be more accurate; 
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− the possibility to eliminate stock outs of product categories with high level of 
inventory turnover, 
− leading to improved revenue and customer satisfaction; 
− provide vendors with real-time visibility of inventory, product is automatically 
registered as it passes through RFID-equipped dock doors, providing location 
information; 
− a strong link is created between package, unit and pallets level; 
− RFID tagging process does not affect the supply chain throughput. 
 
Although RFID has demonstrated considerable benefits in counterfeit prevention, there 
are numerous challenges in the global adoption of such technology. 
Implementation of an RFID system is costly, time-consuming and difficult. The 
problems encountered in a typical case study as well as its solutions are explained and 
discussed below:  
1. Cost issue. Cost is the most remarkable challenge in adopting the RFID technology. 
The tag cost and customization cost demands companies to invest enormously in 
building the network. Thus, it is learnt that effective containment of costs is critical 
to successful RFID implementations. Phased implementation is one of the suggested 
solutions that will benefit the company within the shortest period of time. 
Furthermore, leveraging experience gained from the pilot implementation would 
help companies to replicate successes and avoid danger in full-scale roll out of the 
solution and minimize wasted investment.  
In the table below the main costs for the implementation of the RFID system inside 
Harmonic company (case study page 69), are reported: 
Implementation cost  
RFID hardware set up cost (1 RFID printer + 
7 EPC compliant, multi-protocol reader ) 
15200 € 
Software customisation cost 10500 € 
Monthly running cost  
RFID tags (€0,20 * 2,000 products) 400 € 
Maintenance cost 314 € 
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2. Standardization issue. The penetration power of radio frequency energy depends on 
the transmitter power of the reader and duty cycle. These are regulated in many 
countries around the world. For example, a reader might fail to communicate with 
the tag attached to a product because it is designed to operate at different 
frequencies. This type of detection problem discourages many supply chain parties 
from adopting the RFID technology because they are uncertain about the 
effectiveness of the system they invested in. In the absence of a globally unified 
RFID frequency band, company should standardize the operational bands of the 
RFID system components used by the collaborating parties. 
3. People and organizational resistance. People will typically reject a new approach 
when the existing process has to be significantly changed.  
4. ePedigree defining issue. With the help of RFID and EPC, the ePedigree can be 
formed according to the captured information. Numerous issues remain open 
question and require further study, such as future transaction volumes, information 
storage (how long will the organization be required to store the drug pedigrees?), 
reliability and certification (when will the pedigree be required to register the 
information once the product is shipped or is at other stages?), etc. 
5. RFID Difficult Materials. The materials that make up the medications are mainly 
metal and liquid; both materials can highly affect the way radio waves behave when 
you are intending to identify via RFID tags in close proximity to them. To resolve 
this problem, it can be used  a UHF EPC Global Gen2, but this may increase the cost 
of the implementation. 
6. Manufacturing Process Speed. Packaging lines for pharmaceutical products tend to 
operate at high speeds capable of producing hundreds of units per minute. So it is 
needed to verify the premise that the use of this technology should not affect 
manufacturing processes speed. 
7. Reading and Writing Process. Reading and writing variable data onto individually 
RFID tagged products moving at high speed and which additionally are packaged in 
metallic blister packs is extremely complex. The use of UHF RFID bulk encoding 
technology and the state of the art of software capable of writing via RFID to 
multiple units per pack at high speeds provided, this challenge can be addressed 
successfully. 
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The healthcare world is a large complex network of legislation, corporations, and fast 
growing technology.  
In healthcare RFID is growing very rapidly and is projected to grow further into a $2.1 
billion industry by 2016.  
With the FDA’s interest in e-pedigrees and the State of California’s new requirement of 
individual serial numbers for each pharmaceutical unit, the supply chains of the past are 
being changed forever.   
The results of the Viagra pilot, conducted by Pfizer, have further added to the success 
stories of RFID used in the itemized world of pharmaceuticals.   
The requirements of the pharmaceutical industry are very different from those of any 
other industry and this is reflected in its rapid adoption of RFID.  
Even the FDA recommended that all item level prescribed drugs supplied into the US 
market be RFID tagged within two years.  
This is not going to happen on time, partly because of the thoroughness applied in 
investigating whether HF or UHF is the best solution and work on standards and what 
security and data handling should be used in the computer systems.  
However, a good start has been made. The world's largest drug company Pfizer, which 
had earlier led the way in using 2D barcodes on drugs, has once again led the way with 
item level RFID, tagging all packages of Viagra from December 2005.  
Viagra and Trizivir are already tagged in the US. Trizivir an HIV medicine, is one of 
the 32 drugs listed as most susceptible to counterfeiting and diversion.  
As each bottle of Viagra moves down the packaging line, a label with an integrated 
passive high-frequency (13.56 MHz) tag is applied.  
An RFID interrogator then encodes an EPC to each label, after which a second 
interrogator verifies the tag has been successfully encoded and can be read.  
The interrogator also reads the unique ID number stored on the tag's chip by the chip's 
manufacturer, enabling Pfizer to record both the chip ID and the item's EPC in a 
database.  
Pharmacists and wholesalers will use the tags to authenticate the drug. If the EPC was 
not issued by Pfizer, or if the chip ID does not match the one in Pfizer's records for that 
EPC, the Authentication Service sends a notice, through the authentication application, 
to the pharmacist or wholesaler to quarantine the product.  
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Authentication Service also contacts Pfizer's Medical Information Services, a group of 
Pfizer employees who process suspected cases of counterfeit drugs and would likely ask 
the pharmacist or wholesaler to send the suspected bottle of Viagra back to Pfizer for 
investigation. 
 
The introduction of the RFID inside a company can be seen as a Business Process 
Reengineering project, and like in every BPR project, not all the functionalities can be 
implemented from the beginning in the industry, because of the difficulty in managing 
the change and the high level of costs in implementing the identified solution. 
So an effective change management is needed, because the introduction of a new 
technology requires changes in people behaviour and culture and processes.  
As a result, there are many factors that prevent the effective implementation of RFID 
system; one of the most overlooked obstacles to successful BPR project implementation 
is resistance from those people more impacted by the change. Most projects 
underestimate the cultural impact of major process and structural change and as a result, 
do not achieve the full potential of their change effort.  
So it is important to introduce first a pilot project and only after try to extend the 
technology in every part of the supply chain and to increase the number of functions 
able to be implemented by this technology. 
Surely in the short term it is not possible to introduce the track and trace functionality 
because of the high cost of the needed technology and the fact that technology is still on 
his infancy from this point of view, and then really few companies are adopting the tags 
for this purpose.  
By the time when more companies will be using the technology for this aim, its cost is 
going to be lower. 
For example, Gador S.A, a leading pharmaceuticals company based in Argentina, 
decided to introduce the RFID solution inside its supply chain in order to have more 
visibility and ensure quality and safety of its products. 
The first step in the project was to form a taskforce; several studies and tests simulating 
the usual processes of packaging the product by Gador, were conducted. The pilot 
project included all stages of  packaging process, from item level identification to 
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complete control of pallets in the production line. 
The results of the pilot were extremely successful, confirming the use of RFID 
technology in the identification of drugs, can be safe tool which does not adversely 
affect the packaging and logistics processes and at the same time optimizes the 
traceability of these products unequalled previously. 
In the manufacturing process the carton boxes are loaded into the machine that will 
perform the packaging of the blister packs. At this stage there are two ways to perform 
the identification of the products with RFID, the first is on an individual basis (or item 
level) and the second is in bulk. They decided to build a pallet of 360 packs. 
So as guarantee the correct traceability of the medications, a correct link must be 
established between the individual cartons that make up a pack and the pack itself.  
Once a pallet with 360 packs (total of 7200 individual cartons) has been created, an 
RFID pallet Tag must be generated which maintains the relationship between individual 
carton, pack and pallet. This process requires the correct reading of all the packs that 
make up a pallet in order to link them with the identification of the pallet in question. 
Product safety is a complicated and important issue, as well as a major challenge to 
global trade. There is much concern in the industry and from its large healthcare clients 
and their patients, about whether a drug that has been prescribed is authentic or not.  
The pharmaceutical industry estimates that between 2 and 7 percent of all drugs sold 
globally are counterfeited. When a situation like this occurs, there is serious impact on 
the drug company's share price.  
 
RFID technology makes it easier to ensure that drugs are authentic, and it also creates 
an electronic pedigree, or record of the chain of custody, from the point of manufacture 
to the point of dispensing.  
Electronic pedigrees will improve patient safety and protect the public health by 
allowing wholesalers and retailers to rapidly identify, quarantine, and report suspected 
counterfeit drugs and conduct efficient, targeted recalls.  
The use of the combination between EPC and RFID allows the supply chain network to 
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enhance the track and trace capabilities of product movement and anti-counterfeiting 
within the supply chain.  
One of the obvious strengths of the proposed system is its ability to track and trace the 
product anywhere and anytime. In particular, the system is not only limited to depicting 
product supply chain information to authorized parties, but it can also integrate such 
information with other applications to support decision making and communication. 
This new network provides support and consideration for manufacturers in particular to 
further adopt the application in a global and standardized fashion, so as to realize its full 
potential as an authentication solution and supply chain analyser. 
In conclusion, it is possible to say that the RFID is mainly able to solve most of the 
problems faced by the pharmaceutical supply chain; this doesn’t mean that it is the only 
viable technology, but it is the most effective one. 
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Conclusion 
 
There can be no doubt that the pharmaceutical industry is changing: the maturation of 
the emerging markets has transformed conventional thinking with regard to business 
competitiveness, extending the supply chain has become a mainstay of most 
competitive strategies.  
Along with this expansion, the challenges in securing products as they move through 
the supply chain have continued to escalate. In the U.S., drug diversion and 
counterfeiting cost this industry approximately 10 percentage of total revenue. 
On the other side the FDA has not ignored the issue of securing the expanding supply 
chain: it issued its first guidance on e-pedigree in 2006.  
The basic concept of an e-pedigree is to create a digital audit trail using digital 
signatures layered one upon the other to demonstrate control and verification at all key 
phases of the supply chain. Today, several technologies can achieve this type of 
integrity; from a technology perspective the clear front-runner is RFID. 
 
The promise of RFID is undeniable, but it is important to understand its technological 
limitations before launching into an RFID implementation. RFID tags can be grouped 
into four basic categories:  passive tags, semi-passive tags, semi-active tags and active 
tags, as discussed in chapter one. Passive tags are by far the mostly broadly 
implemented and span several market sectors; these are designed to simply store data 
that can be read by a reader. They are the lowest priced technology. They do not possess 
any intelligence or security. On the other hand, active tags typically come equipped with 
a lithium battery and can emit a signal periodically, these tags can easily cost from $20 
to $150 per unit. 
 
Understanding what the supply chain needs is one key element in selecting the 
appropriate tag: another is recognising the risks of implementation.  
 
So a lot of issues are still to be solved before a full application of this technology will be 
possible in the pharmaceutical industry and many organisations and governmental 
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agencies are trying to address these problems, because the pharmaceutical supply chain 
is critical not only for the industry itself, but even for the whole society. 
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